Robert Peter Gale

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6776970/publications.pdf

Version: 2024-02-01

905 papers	43,122 citations	1994 101 h-index	3915 177 g-index
933 all docs	933 docs citations	933 times ranked	22208 citing authors

#	Article	IF	Citations
1	Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature, 1985, 315, 550-554.	27.8	1,549
2	Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Leukemia. New England Journal of Medicine, 2004, 351, 2265-2275.	27.0	1,019
3	Solid Cancers after Bone Marrow Transplantation. New England Journal of Medicine, 1997, 336, 897-904.	27.0	914
4	Bone Marrow Transplantation for Chronic Myelogenous Leukemia in Chronic Phase. Annals of Internal Medicine, 1988, 108, 806.	3.9	786
5	Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 1990, 75, 555-62.	1.4	738
6	Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.. Journal of Clinical Oncology, 1990, 8, 813-819.	1.6	719
7	Opioid Peptides Mediate the Suppressive Effect of Stress on Natural Killer Cell Cytotoxicity. Science, 1984, 223, 188-190.	12.6	629
8	IBMTR Severity INDEX FOR GRADING ACUTE GRAFTâ€VERSUSâ€HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE. British Journal of Haematology, 1997, 97, 855-864.	2.5	605
9	Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood, 2012, 119, 296-307.	1.4	559
10	Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood, 2002, 100, 406-414.	1.4	503
11	Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell, 1986, 47, 277-284.	28.9	484
12	Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood, 1999, 94, 2208-16.	1.4	482
13	Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome. Journal of Clinical Oncology, 2010, 28, 1878-1887.	1.6	459
14	Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings.. Journal of Clinical Oncology, 1997, 15, 1767-1777.	1.6	440
15	Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood, 2000, 95, 3702-9.	1.4	378
16	COVID-19 in persons with haematological cancers. Leukemia, 2020, 34, 1637-1645.	7.2	373
17	Intravenous Immunoglobulin for the Prevention of Infection in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 1988, 319, 902-907.	27.0	369
18	Interstitial Pneumonitis After Bone Marrow Transplantation. Annals of Internal Medicine, 1986, 104, 168.	3.9	354

#	Article	IF	Citations
19	Increasing Incidence of Chronic Graft-versus-Host Disease inÂAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 266-274.	2.0	331
20	Antithymocyte Globulin Treatment in Patients with Aplastic Anemia. New England Journal of Medicine, 1983, 308, 113-118.	27.0	328
21	High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.. Journal of Clinical Oncology, 1997, 15, 1870-1879.	1.6	325
22	Risk factors for acute graftâ€versusâ€host disease. British Journal of Haematology, 1987, 67, 397-406.	2.5	315
23	Intravenous Immune Globulin for Prevention of Cytomegalovirus Infection and Interstitial Pneumonia After Bone Marrow Transplantation. Annals of Internal Medicine, 1987, 106, 12.	3.9	293
24	Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood, 2002, 99, 1572-1577.	1.4	275
25	Genes on chromosomes 4, 9, and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 4631-4635.	7.1	266
26	Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. Journal of Clinical Oncology, 2013, 31, 2662-2670.	1.6	265
27	Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood, 2007, 110, 1397-1400.	1.4	260
28	Treatment of Donor Bone Marrow with Monoclonal Anti-T-Cell Antibody and Complement for the Prevention of Graft-Versus-Host Disease. Annals of Internal Medicine, 1986, 105, 20.	3.9	255
29	Identical-Twin Bone Marrow Transplants for Leukemia. Annals of Internal Medicine, 1994, 120, 646.	3.9	252
30	Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood, 2001, 97, 1598-1603.	1.4	252
31	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood, 2016, 127, 938-947.	1.4	246
32	Outcome of Transplantation for Myelofibrosis. Biology of Blood and Marrow Transplantation, 2010, 16, 358-367.	2.0	245
33	Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplantation, 2012, 47, 203-211.	2.4	245
34	Chronic graft versus host disease: A syndrome of disordered immunity. American Journal of Medicine, 1979, 66, 611-620.	1.5	239
35	Bone Marrow Transplants from HLA-Identical Siblings as Compared with Chemotherapy for Children with Acute Lymphoblastic Leukemia in a Second Remission. New England Journal of Medicine, 1994, 331, 1253-1258.	27.0	224
36	Cloning of the ALL-1 fusion partner, the AF-6 gene, involved in acute myeloid leukemias with the t(6;11) chromosome translocation. Cancer Research, 1993, 53, 5624-8.	0.9	224

#	Article	IF	Citations
37	Comparison of Preparative Regimens in Transplants for Children With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2000, 18, 340-340.	1.6	222
38	Cytomegalovirus Immune Plasma in Bone Marrow Transplant Recipients. Annals of Internal Medicine, 1982, 97, 11.	3.9	219
39	HLA-Identical Sibling Bone Marrow Transplantation in Younger Patients with Chronic Lymphocytic Leukemia. Annals of Internal Medicine, 1996, 124, 311.	3.9	217
40	Stress increases metastatic spread of a mammary tumor in rats: Evidence for mediation by the immune system. Brain, Behavior, and Immunity, 1991, 5, 193-205.	4.1	215
41	Bone marrow origin of hepatic macrophages (Kupffer cells) in humans. Science, 1978, 201, 937-938.	12.6	214
42	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood, 2017, 130, 1156-1164.	1.4	210
43	Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia, 2020, 34, 1503-1511.	7.2	208
44	Advances in the Treatment of Acute Myelogenous Leukemia. New England Journal of Medicine, 1979, 300, 1189-1199.	27.0	207
45	Chronic Lymphocytic Leukemia: New Insights into Biology and Therapy. Annals of Internal Medicine, 1990, 113, 525.	3.9	207
46	Benchmark standards for refractive outcomes after NHS cataract surgery. Eye, 2009, 23, 149-152.	2.1	203
47	Cytomegalovirus Infections Associated with Leukocyte Transfusions. Annals of Internal Medicine, 1980, 93, 671.	3.9	202
48	p53 in chronic myelogenous leukemia in acute phase.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 6293-6297.	7.1	202
49	Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplantation, 2004, 34, 721-727.	2.4	202
50	Measurable residual disease testing in acute myeloid leukaemia. Leukemia, 2017, 31, 1482-1490.	7.2	197
51	Involvement of brain opiate receptors in the immune-suppressive effect of morphine.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 7114-7117.	7.1	196
52	An 8-kilobase abl RNA transcript in chronic myelogenous leukemia.. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 5648-5652.	7.1	191
53	A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia. Nature, 1987, 330, 386-388.	27.8	190
54	Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease.. Journal of Clinical Oncology, 1996, 14, 572-578.	1.6	190

#	Article	IF	Citations
55	Allogeneic bone marrow transplantation for low-grade lymphoma. Blood, 1998, 92, 1832-6.	1.4	190
56	Autotransplants for Hodgkin's Disease in Patients Never Achieving Remission: A Report From the Autologous Blood and Marrow Transplant Registry. Journal of Clinical Oncology, 1999, 17, 534-534.	1.6	186
57	Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood, 2010, 115, 1850-1857.	1.4	184
58	Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. British Journal of Haematology, 1988, 69, 239-245.	2.5	183
59	A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing Sibling Allografting for Acute Lymphoblastic Leukemia in First or Second Complete Remission. Biology of Blood and Marrow Transplantation, 2006, 12, 438-453.	2.0	182
60	Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia, 2017, 31, 1855-1868.	7.2	181
61	Clinical Uses of Intravenous Immunoglobulins. Annals of Internal Medicine, 1990, 112, 278.	3.9	169
62	Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis carinii Pneumonia. Annals of Internal Medicine, 1980, 92, 762.	3.9	168
63	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. Journal of Clinical Oncology, 2015, 33, 3741-3749.	1.6	163
64	Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. British Journal of Haematology, 2007, 137, 479-485.	2.5	161
65	Risk Factors for Acute Graft-Versus-Host Disease After Human Leukocyte Antigenâ€“Identical Sibling Transplants for Adults With Leukemia. Journal of Clinical Oncology, 2008, 26, 5728-5734.	1.6	159
66	Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced-Intensity Compared to Myeloablative Conditioning. Biology of Blood and Marrow Transplantation, 2008, 14, 236-245.	2.0	157
67	Therapeutic Granulocyte Transfusions for Documented Infections. Annals of Internal Medicine, 1982, 97, 509.	3.9	152
68	A Controlled Trial of Prophylactic Granulocyte Transfusions during Initial Induction Chemotherapy for Acute Myelogenous Leukemia. New England Journal of Medicine, 1981, 305, 597-603.	27.0	150
69	Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplantation, 1991, 7, 443-52.	2.4	150
70	Pneumococcal Infections After Human Bone-Marrow Transplantation. Annals of Internal Medicine, 1979, 91, 835.	3.9	148
71	The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood, 2009, 113, 3110-3118.	1.4	147
72	Treatment of Acute Myelogenous Leukemia. Annals of Internal Medicine, 1985, 102, 285.	3.9	145

#	Article	IF	Citations
73	Chemotherapy Compared with Bone Marrow Transplantation for Adults with Acute Lymphoblastic Leukemia in First Remission. Annals of Internal Medicine, 1991, 115, 13.	3.9	145
74	Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood, 2005, 105, 1408-1416.	1.4	144
75	Bone Marrow Transplantation after the Chernobyl Nuclear Accident. New England Journal of Medicine, 1989, 321, 205-212.	27.0	141
76	Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica, 2010, 95, 2119-2125.	3.5	137
77	HYBRID ACUTE LEUKAEMIA. British Journal of Haematology, 1987, 65, 261-264.	2.5	137
78	Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplantation, 1989, 4, 247-54.	2.4	135
79	Chronic Lymphocytic Leukemia. Annals of Internal Medicine, 1985, 103, 101.	3.9	132
80	Aplastic anemia and non-A, non-B hepatitis. American Journal of Medicine, 1983, 74, 64-68.	1.5	130
81	Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2014, 20, 89-97.	2.0	130
82	Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients. American Journal of Medicine, 1984, 77, 442-450.	1.5	129
83	Intensive Chemotherapy for Acute Myelogenous Leukemia. Annals of Internal Medicine, 1981, 94, 753.	3.9	128
84	Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood, 2011, 117, 6714-6720.	1.4	128
85	Chronic myeloid leukemia stem cells. Leukemia, 2019, 33, 1543-1556.	7.2	127
86	ABO Blood Group Barrier in Allogeneic Bone Marrow Transplantation Revisited. Biology of Blood and Marrow Transplantation, 2005, 11, 1006-1013.	2.0	124
87	T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood, 2000, 95, 3996-4003.	1.4	124
88	Origin of Human Bone Marrow Fibroblasts. British Journal of Haematology, 1980, 44, 183-187.	2.5	121
89	Apparent involvement of opioid peptides in stress-induced enhancement of tumor growth. Peptides, 1983, 4, 635-638.	2.4	121
90	Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia, 2014, 28, 658-665.	7.2	121

#	Article	IF	Citations
91	Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplantation, 1998, 21, 1231-1238.	2.4	118
92	Polymorphonuclear leukocytes in antibody-dependent cellular cytotoxicity. Journal of Immunology, 1975, 114, 1047-51.	0.8	117
93	Ofloxacin versus Vancomycin/Polymyxin for prevention of infections in granulocytopenic patients. American Journal of Medicine, 1990, 88, 36-42.	1.5	116
94	HLA-matched sibling bone marrow transplantation for Î²-thalassemia major. Blood, 2011, 117, 1745-1750.	1.4	114
95	Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplantation, 1998, 21, 153-158.	2.4	113
96	Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. British Journal of Haematology, 1999, 104, 392-396.	2.5	110
97	Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. American Journal of Medicine, 1986, 80, 884-890.	1.5	108
98	Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplantation, 2001, 27, 387-396.	2.4	106
99	Risk factors for death in 1859 subjects with COVID-19. Leukemia, 2020, 34, 2173-2183.	7.2	105
100	USE OF RECOMBINANT GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR IN THE BRAZIL RADIATION ACCIDENT. Lancet, The, 1988, 332, 471-475.	13.7	104
101	Hematological features of persons with COVID-19. Leukemia, 2020, 34, 2163-2172.	7.2	103
102	Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplantation, 1992, 9, 269-75.	2.4	103
103	Controversies in the therapy of acute myelogenous leukemia. American Journal of Medicine, 1982, 72, 963-979.	1.5	102
104	In vitro hepatitis B virus infection of human bone marrow cells.. Journal of Clinical Investigation, 1986, 78, 411-417.	8.2	102
105	Graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transplantation, 1987, 2, 233-42.	2.4	102
106	Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood, 2000, 96, 1254-8.	1.4	102
107	Intravenous Immunoglobulins as Therapeutic Agents. Annals of Internal Medicine, 1987, 107, 367.	3.9	100
108	Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 1615-1624.	2.0	99

#	Article	IF	Citations
109	Salvage Second Hematopoietic Cell Transplantation inÂMyeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 760-766.	2.0	98
110	Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2014, 20, 402-408.e1.	2.0	98
111	Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. Clinical Cancer Research, 2015, 21, 2020-2028.	7.0	98
112	Bone marrow transplantation for severe aplastic anemia: has outcome improved?. Blood, 1997, 90, 858-64.	1.4	98
113	Hybrid acute leukemia. Leukemia Research, 1984, 8, 929-936.	0.8	92
114	Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation. American Journal of Medicine, 1984, 76, 128-133.	1.5	92
115	Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. British Journal of Haematology, 2002, 119, 1115-1124.	2.5	92
116	Prophylactic granulocyte transfusions during human bone marrow transplantation. American Journal of Medicine, 1980, 68, 893-897.	1.5	91
117	Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2013, 19, 625-631.	2.0	91
118	A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood, 1979, 53, 504-14.	1.4	91
119	Molecular Epidemiology of Cytomegalovirus Infections Associated with Bone Marrow Transplantation. Annals of Internal Medicine, 1985, 102, 16.	3.9	89
120	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Advances, 2019, 3, 1826-1836.	5.2	89
121	A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large BÂCell Lymphoma: A Report from the CIBMTR. Biology of Blood and Marrow Transplantation, 2010, 16, 35-45.	2.0	88
122	Long-Term Follow-up of Adults with Acute Lymphoblastic Leukemia in First Remission Treated with Chemotherapy or Bone Marrow Transplantation. Annals of Internal Medicine, 1995, 123, 428.	3.9	87
123	Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplantation, 2014, 49, 1360-1365.	2.4	87
124	Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplantation, 1995, 16, 203-8.	2.4	87
125	Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood, 2006, 107, 1712-1716.	1.4	85
126	Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia, 2012, 26, 1091-1097.	7.2	85

#	Article	IF	Citations
127	Immunoblastic Sarcoma in Donor Cells after Bone-Marrow Transplantation. New England Journal of Medicine, 1979, 300, 904-907.	27.0	84
128	What are RBC-transfusion-dependence and -independence?. Leukemia Research, 2011, 35, 8-11.	0.8	84
129	Effects of a single administration of morphine or footshock stress on natural killer cell cytotoxicity. Brain, Behavior, and Immunity, 1987, 1, 318-328.	4.1	83
130	Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplantation, 2012, 47, 810-816.	2.4	83
131	Impact of Pretransplantation Conditioning Regimens onÂOutcomes of Allogeneic Transplantation for Chemotherapy-Unresponsive Diffuse Large B Cell Lymphoma and Grade III Follicular Lymphoma. Biology of Blood and Marrow Transplantation, 2013, 19, 746-753.	2.0	83
132	Designed transfer of specific immune responses with bone marrow transplantation.. Journal of Clinical Investigation, 1986, 78, 959-967.	8.2	83
133	Advanced Breast Cancer: High-Dose Chemotherapy and Bone Marrow Autotransplants. Annals of Internal Medicine, 1988, 108, 570.	3.9	82
134	Effects of footshock stress and morphine on natural killer lymphocytes in rats: studies of tolerance and cross-tolerance. Brain Research, 1986, 372, 382-385.	2.2	81
135	Is the international staging system superior to the Durieâ€“Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia, 2009, 23, 1528-1534.	7.2	81
136	Alveolar macrophage dysfunction in human bone marrow transplant recipients. American Journal of Medicine, 1982, 73, 859-866.	1.5	79
137	Recent Advances in the Biology and Treatment of Acute Lymphoblastic Leukemia in Adults. New England Journal of Medicine, 1984, 311, 1219-1231.	27.0	79
138	Improved survival after acute graft- versus -host disease diagnosis in the modern era. Haematologica, 2017, 102, 958-966.	3.5	79
139	Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. Blood, 1998, 91, 1810-9.	1.4	79
140	Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. British Journal of Haematology, 2003, 121, 874-885.	2.5	77
141	Bone marrow transplantation from identical twins in the treatment of aplastic anaemia: implication for the pathogenesis of the disease. British Journal of Haematology, 1984, 56, 455-463.	2.5	76
142	Paraplegia following intrathecal cytosine arabinoside. Cancer, 1979, 43, 83-85.	4.1	75
143	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplantation, 2018, 53, 535-555.	2.4	75
144	Decreased chronic lymphocytic leukemia incidence in Asians in Los Angeles County. Leukemia Research, 2000, 24, 665-669.	0.8	74

#	Article	IF	Citations
145	COVID-19 in persons with chronic myeloid leukaemia. Leukemia, 2020, 34, 1799-1804.	7.2	74
146	Suppression of natural killer cell activity by high-dose narcotic anesthesia in rats. Brain, Behavior, and Immunity, 1989, 3, 129-137.	4.1	73
147	Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1796-1803.	2.0	73
148	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 726-733.	2.0	71
149	Autologous stem cell transplantation in multiple myeloma patients <60 vs â©¾60 years of age. Bone Marrow Transplantation, 2003, 32, 1135-1143.	2.4	70
150	Results of Transplanting Bone Marrow from Genetically Identical Twins into Patients with Aplastic Anemia. Annals of Internal Medicine, 1997, 126, 116.	3.9	69
151	Allogeneic Hematopoietic Cell Transplantation for Fanconi Anemia in Patients With Pretransplantation Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia. Journal of Clinical Oncology, 2013, 31, 1669-1676.	1.6	69
152	Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood, 2000, 95, 3323-7.	1.4	69
153	ABH Antigens and Bone Marrow Transplantation. British Journal of Haematology, 1980, 44, 65-73.	2.5	68
154	Autotransplants in chronic myelogenous leukaemia: strategies and results. Lancet, The, 1990, 335, 1255-1258.	13.7	68
155	Autologous or Allogeneic Stem Cell Transplantation in Patients with Waldenstromâ€™s Macroglobulinemia. Biology of Blood and Marrow Transplantation, 2006, 12, 845-854.	2.0	68
156	Factors Correlated With Progression-Free Survival After High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Metastatic Breast Cancer. JAMA - Journal of the American Medical Association, 1999, 282, 1335.	7.4	66
157	Prior rituximab correlates with less acute graftâ€versusâ€host disease and better survival in Bâ€cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. British Journal of Haematology, 2009, 145, 816-824.	2.5	66
158	Expression of the normal p53 gene induces differentiation of K562 cells. Oncogene, 1992, 7, 1853-7.	5.9	66
159	Modulation of polymorphonuclear leukocyte-mediated antibody-dependent cellular cytotoxicity. Journal of Immunology, 1974, 113, 1793-800.	0.8	66
160	Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplantation, 1996, 17, 75-80.	2.4	66
161	Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. Cancer, 2017, 123, 3141-3149.	4.1	65
162	Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia, 1996, 10, 13-9.	7.2	65

#	Article	IF	Citations
163	High-dose combined-modality therapy and autologous bone marrow transplantation in resistant cancer. American Journal of Medicine, 1981, 71, 973-976.	1.5	64
164	Aplastic Anemia: Biology and Treatment. Annals of Internal Medicine, 1981, 95, 477.	3.9	64
165	Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 335-341.	2.0	64
166	Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation. Leukemia, 2016, 30, 285-294.	7.2	64
167	Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved. Blood Reviews, 2021, 47, 100773.	5.7	63
168	JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis. Leukemia, 2021, 35, 2616-2620.	7.2	63
169	Infectious complications of bone marrow transplantation. Experimental Hematology, 1984, 12, 205-15.	0.4	63
170	Risk factors for interstitial pneumonia following bone marrow transplantation for severe aplastic anaemia. British Journal of Haematology, 1989, 71, 535-543.	2.5	62
171	Genetic Relatedness of Lymphoid Malignancies: Transformation of Chronic Lymphocytic Leukemia as a Model. Annals of Internal Medicine, 1993, 119, 63.	3.9	62
172	Transplantation for Autoimmune Diseases in North and South America: A Report of the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2012, 18, 1471-1478.	2.0	62
173	Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood, 1992, 80, 1090-3.	1.4	62
174	High-Dose Versus Standard Chemotherapy in Metastatic Breast Cancer: Comparison of Cancer and Leukemia Group B Trials With Data From the Autologous Blood and Marrow Transplant Registry. Journal of Clinical Oncology, 2002, 20, 743-750.	1.6	61
175	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Journal of Clinical Oncology, 2016, 34, 1864-1871.	1.6	61
176	bcr genes and transcripts. Oncogene, 1988, 2, 113-7.	5.9	61
177	Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation. Cancer, 1982, 49, 1789-1795.	4.1	60
178	Comparison of Outcomes after Transplantation of G-CSFâ€“Stimulated Bone Marrow Grafts versus Bone Marrow or Peripheral Blood Grafts from HLA-Matched Sibling Donors for Patients with Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2011, 17, 1018-1024.	2.0	60
179	THE MOLECULAR BIOLOGY OF CHRONIC MYELOGENOUS LEUKAEMIA. British Journal of Haematology, 1985, 60, 395-408.	2.5	59
180	The mystery of chronic lymphocytic leukemia (CLL): Why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology?. Blood Reviews, 2015, 29, 205-213.	5.7	59

#	Article	IF	Citations
181	2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clinical Transplants, 2010, , 87-105.	0.2	57
182	Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. British Journal of Haematology, 2006, 132, 755-769.	2.5	56
183	Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant. Biology of Blood and Marrow Transplantation, 2008, 14, 904-912.	2.0	56
184	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. Biology of Blood and Marrow Transplantation, 2015, 21, 2091-2099.	2.0	55
185	NK-/T-cell lymphomas. Leukemia, 2021, 35, 2460-2468.	7.2	55
186	T cell depletion in bone marrow transplantation for leukemia: current results and future directions. Bone Marrow Transplantation, 1988, 3, 185-92.	2.4	55
187	Gene Markers in Human Bone Marrow Transplantation¹. Vox Sanguinis, 1977, 33, 202-205.	1.5	54
188	A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. Leukemia, 2017, 31, 896-902.	7.2	54
189	A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia. Blood, 2019, 134, 557-557.	1.4	54
190	Maintenance chemotherapy and cure of childhood acute lymphoblastic leukaemia. Lancet, The, 1991, 338, 1315-1318.	13.7	53
191	Acute myelogenous leukemia: Morphologic classification and response to therapy. Leukemia Research, 1979, 3, 171-173.	0.8	52
192	Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission. Biology of Blood and Marrow Transplantation, 2004, 10, 116-127.	2.0	52
193	Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2009, 15, 1455-1464.	2.0	52
194	Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans. Oncotarget, 2015, 6, 5426-5434.	1.8	52
195	High dose cytarabine: a review. Leukemia, 1988, 2, 253-60.	7.2	52
196	Immediate Medical Consequences of Nuclear Accidents. JAMA - Journal of the American Medical Association, 1987, 258, 625.	7.4	51
197	HLA-Identical Sibling Allogeneic Transplants versus Chemotherapy in Acute Myelogenous Leukemia with t(8;21) in First Complete Remission: Collaborative Study between the German AML Intergroup and CIBMTR. Biology of Blood and Marrow Transplantation, 2008, 14, 187-196.	2.0	51
198	Second transplants for multiple myeloma relapsing after a previous autotransplantâ€"reduced-intensity allogeneic vs autologous transplantation. Bone Marrow Transplantation, 2014, 49, 416-421.	2.4	51

#	Article	IF	Citations
199	Calreticulin mutations in Chinese with primary myelofibrosis. Haematologica, 2014, 99, 1697-1700.	3.5	50
200	JAK2V617F allele burden â©¾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy. Leukemia, 2016, 30, 1772-1775.	7.2	50
201	Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report. Biology of Blood and Marrow Transplantation, 2017, 23, 1342-1349.	2.0	50
202	Acute lymphoblastic leukemia in adults: recent progress, future directions. Seminars in Hematology, 1987, 24, 27-39.	3.4	50
203	Prophylactic Granulocyte Transfusions During Chemotherapy of Acute Nonlymphocytic Leukemia. Annals of Internal Medicine, 1981, 94, 616.	3.9	49
204	Arrhythmias in the setting of hematopoietic cell transplants. Bone Marrow Transplantation, 2015, 50, 1212-1216.	2.4	49
205	A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. American Journal of Hematology, 2018, 93, 803-809.	4.1	49
206	Cellular therapy for acute myeloid Leukemia â€“ Current status and future prospects. Blood Reviews, 2019, 37, 100578.	5.7	49
207	Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. Leukemia, 2021, 35, 1563-1570.	7.2	49
208	CHEMOTHERAPY VERSUS TRANSPLANTATION IN ACUTE LEUKAEMIA. British Journal of Haematology, 1989, 72, 1-8.	2.5	48
209	Ethanol increases tumor progression in rats: Possible involvement of natural killer cells. Brain, Behavior, and Immunity, 1992, 6, 74-86.	4.1	48
210	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2015, 21, 1746-1753.	2.0	48
211	Improved survival following bone marrow transplantation for aplastic anaemia. British Journal of Haematology, 1983, 54, 509-517.	2.5	48
212	Bone Marrow Transplantation in Man. Annals of Internal Medicine, 1975, 83, 691.	3.9	47
213	Effects of long-term cryopreservation on hematopoietic progenitor cells in umbilical cord blood. Bone Marrow Transplantation, 1999, 23, 395-396.	2.4	47
214	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leukemia Research, 2018, 74, 130-136.	0.8	47
215	Regeneration of T cell subpopulations after bone marrow transplantation: cytomegalovirus infection and lymphoid subset imbalance. Journal of Immunology, 1982, 129, 1926-30.	0.8	47
216	Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission. Bone Marrow Transplantation, 1998, 22, 253-257.	2.4	46

#	Article	IF	Citations
217	Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica, 2017, 102, 85-93.	3.5	46
218	Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?. Leukemia, 2020, 34, 671-681.	7.2	46
219	Nucleotide sequence analysis of human abl and bcr-abl cDNAs. Oncogene, 1989, 4, 1477-81.	5.9	46
220	MPN-associated myelofibrosis (MPN-MF). Leukemia Research, 2011, 35, 12-13.	0.8	45
221	Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions. Leukemia Research, 2014, 38, 545-550.	0.8	45
222	A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplantation, 2015, 50, 1416-1423.	2.4	45
223	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer, 2016, 122, 3005-3014.	4.1	45
224	Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1539-1547.	2.5	45
225	Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report from The Center For International Blood & Marrow Transplant Research (CIBMTR). Biology of Blood and Marrow Transplantation, 2008, 14, 1323-1333.	2.0	44
226	Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. Bone Marrow Transplantation, 2017, 52, 1616-1622.	2.4	44
227	Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia. Leukemia, 2016, 30, 1230-1236.	7.2	43
228	Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 228-241.	2.0	43
229	Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s. Bone Marrow Transplantation, 1991, 8, 7-11.	2.4	43
230	Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review. Leukemia, 1987, 1, 575-9.	7.2	43
231	Therapy of acute myelogenous leukemia. Seminars in Hematology, 1987, 24, 40-54.	3.4	43
232	The early complications of bone marrow transplantation. Seminars in Hematology, 1984, 21, 101-8.	3.4	43
233	E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy. Haematologica, 2017, 102, e297-e299.	3.5	42
234	GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. Bone Marrow Transplantation, 2017, 52, 400-408.	2.4	42

#	Article	IF	Citations
235	VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder. Experimental Hematology and Oncology, 2021, 10, 23.	5.0	42
236	Abnormalities of myeloid progenitor cells after "successful" bone marrow transplantation.. Journal of Clinical Investigation, 1985, 75, 234-241.	8.2	42
237	HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions. Leukemia, 2021, 35, 3040-3043.	7.2	42
238	Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplantation, 2008, 41, 537-545.	2.4	41
239	Commentary: does immune suppression increase risk of developing acute myeloid leukemia?. Leukemia, 2012, 26, 422-423.	7.2	41
240	MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma. Blood Cancer Journal, 2017, 7, e582-e582.	6.2	41
241	GM-CSF incubation prior to treatment with cytarabine or doxorubicin enhances drug activity against AML cells in vitro: A model for leukemia chemotherapy. Leukemia Research, 1990, 14, 743-749.	0.8	40
242	Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation. Blood Reviews, 2018, 32, 106-115.	5.7	40
243	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 362-368.	2.0	40
244	Amsacrine: A review. Leukemia Research, 1986, 10, 1257-1265.	0.8	39
245	Immune Interventions in Disease. Annals of Internal Medicine, 1987, 106, 257.	3.9	39
246	Impact of Pretransplantation 18F-fluorodeoxy Glucoseâ€“Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2015, 21, 1605-1611.	2.0	39
247	New drug approvals in acute myeloid leukemia: whatâ€™s the best end point?. Leukemia, 2016, 30, 521-525.	7.2	39
248	Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 1024-1029.	2.0	39
249	Latin America: the next region for haematopoietic transplant progress. Bone Marrow Transplantation, 2017, 52, 671-677.	2.4	39
250	Bone marrow transplantation for acute leukemia: recent advances and comparison with alternative therapies. Seminars in Hematology, 1987, 24, 55-67.	3.4	39
251	Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2013, 19, 173-179.	2.0	38
252	Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. Biology of Blood and Marrow Transplantation, 2017, 23, 1327-1334.	2.0	38

#	Article	IF	Citations
253	Transplantation for accidental acute high-dose total body neutron- and Î³-radiation exposure. Bone Marrow Transplantation, 2002, 29, 935-939.	2.4	37
254	Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia. Biology of Blood and Marrow Transplantation, 2010, 16, 543-547.	2.0	37
255	Unique features of primary myelofibrosis in Chinese. Blood, 2012, 119, 2469-2473.	1.4	37
256	TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes. Leukemia Research, 2013, 37, 305-311.	0.8	37
257	Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, 951-959.	2.0	37
258	Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. Bone Marrow Transplantation, 2015, 50, 197-203.	2.4	37
259	Cancer care in the Palestinian territories. Lancet Oncology, The, 2018, 19, e359-e364.	10.7	37
260	Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors. Haematologica, 2019, 104, 2400-2409.	3.5	37
261	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Advances, 2019, 3, 3123-3131.	5.2	37
262	Antibody dependent cellular cytotoxicity: Cytotoxicity mediated by non T-lymphocytes. Clinical Immunology and Immunopathology, 1974, 3, 193-200.	2.0	36
263	Comparison between bone marrow transplantation and antithymocyte globulin in treatment of young patients with severe aplastic anemia. Journal of Pediatrics, 1984, 105, 920-925.	1.8	36
264	Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. Bone Marrow Transplantation, 2016, 51, 58-66.	2.4	36
265	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. Journal of Clinical Oncology, 2020, 38, 2062-2076.	1.6	36
266	The clinical diagnosis of acute graft-versus-host disease: a diversity of views amongst marrow transplant centers. Bone Marrow Transplantation, 1988, 3, 5-10.	2.4	36
267	Stress and morphine affect survival of rats challenged with a mammary ascites tumor (MAT 13762B). Natural Immunity and Cell Growth Regulation, 1983, 3, 43-50.	0.2	36
268	Hematopoietic recovery after 10-Gy acute total body radiation. Blood, 1994, 83, 596-9.	1.4	36
269	Clinical importance of SF3B1 mutations in Chinese with myelodysplastic syndromes with ring sideroblasts. Leukemia Research, 2012, 36, 1428-1433.	0.8	35
270	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Advances, 2018, 2, 2922-2936.	5.2	35

#	Article	IF	Citations
271	Comparative Analysis of Calcineurin Inhibitorâ€“Based Methotrexate and Mycophenolate Mofetilâ€“Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 73-85.	2.0	35
272	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances, 2022, 6, 339-357.	5.2	35
273	Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry. Blood, 2000, 95, 410-5.	1.4	35
274	Progress in Acute Myelogenous Leukemia. Annals of Internal Medicine, 1984, 101, 702.	3.9	34
275	Blood-derived haematopoietic cell transplants: blood to blood?. Lancet, The, 1991, 337, 961-963.	13.7	34
276	What does total body irradiation do in bone marrow transplants for leukemia?. International Journal of Radiation Oncology Biology Physics, 1991, 20, 631-634.	0.8	34
277	Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help?. Bone Marrow Transplantation, 2013, 48, 203-209.	2.4	34
278	What does MRD in leukemia really mean?. Leukemia, 2014, 28, 1131-1131.	7.2	34
279	Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transplantation, 2015, 50, 1513-1518.	2.4	34
280	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. Biology of Blood and Marrow Transplantation, 2018, 24, 521-528.	2.0	34
281	Rapid progress in chronic myelogenous leukemia. Leukemia, 1988, 2, 321-4.	7.2	34
282	Fatal Veno-occlusive Disease of the Liver Following High-dose 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) and Autologous Bone Marrow Transplantation. American Journal of Clinical Pathology, 1981, 75, 614-617.	0.7	33
283	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 202-208.	2.0	33
284	New Cancers after Autotransplantations for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 738-745.	2.0	33
285	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 248-257.	2.0	33
286	Molecular techniques for the personalised management of patients with chronic myeloid leukaemia. Biomolecular Detection and Quantification, 2017, 11, 4-20.	7.0	33
287	Are We Prepared for Nuclear Terrorism?. New England Journal of Medicine, 2018, 378, 1246-1254.	27.0	33
288	Thymus-dependent lymphocytes in human bone marrow.. Journal of Clinical Investigation, 1975, 56, 1491-1498.	8.2	33

#	Article	IF	Citations
289	Antibody synthesis by bone marrow cells in vitro following primary and booster tetanus toxoid immunization in humans.. Journal of Clinical Investigation, 1984, 73, 1377-1384.	8.2	33
290	Clinical uses of intravenous immunoglobulins. Seminars in Hematology, 1988, 25, 140-58.	3.4	33
291	The role of T-cells in preventing relapse in chronic myelogenous leukemia. Bone Marrow Transplantation, 1987, 2, 351-4.	2.4	33
292	Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia. Experimental Hematology and Oncology, 2015, 4, 14.	5.0	32
293	Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation. Bone Marrow Transplantation, 2020, 55, 843-850.	2.4	32
294	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncology, 2022, 8, 404.	7.1	32
295	Etoposide in leukemia, lymphoma and bone marrow transplantation. Leukemia Research, 1989, 13, 639-650.	0.8	31
296	BCR/ABL and leukemia. Leukemia Research, 1996, 20, 523-529.	0.8	31
297	Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplantation, 2012, 47, 831-837.	2.4	31
298	Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia. BMC Cancer, 2016, 16, 269.	2.6	31
299	Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application. Bone Marrow Transplantation, 2020, 55, 40-47.	2.4	31
300	Acute Lymphoblastic Leukemia with Giant Intracytoplasmic Inclusions. American Journal of Clinical Pathology, 1980, 74, 345-349.	0.7	30
301	Bacterial pyomyositis in a patient with aplastic anaemia. Postgraduate Medical Journal, 1980, 56, 61-62.	1.8	30
302	Immunologic Defects in Young Male Patients with Hepatitis-Associated Aplastic Anemia. Annals of Internal Medicine, 1984, 100, 657.	3.9	30
303	Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms. Leukemia, 2014, 28, 1742-1745.	7.2	30
304	Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response. Blood Cancer Journal, 2018, 8, 9.	6.2	30
305	Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. Leukemia, 2018, 32, 2077-2081.	7.2	30
306	Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries. Biology of Blood and Marrow Transplantation, 2020, 26, 333-342.	2.0	30

#	Article	IF	Citations
307	Do persons with chronic myeloid leukaemia have normal or near normal survival?. Leukemia, 2020, 34, 333-335.	7.2	30
308	Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations. British Journal of Haematology, 2021, 192, 1006-1010.	2.5	30
309	Immunodeficiency following allogeneic bone marrow transplantation. Transplantation Proceedings, 1978, 10, 223-7.	0.6	30
310	1993 progress report from the International Bone Marrow Transplant Registry. Advisory Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplantation, 1993, 12, 97-104.	2.4	30
311	HLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission. Leukemia, 1996, 10, 1687-91.	7.2	30
312	Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 458-463.	0.4	29
313	Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience. Bone Marrow Transplantation, 2013, 48, 1056-1064.	2.4	29
314	Autologous haematopoietic cell transplantation for nonâ€<scp>H</scp>odgkin lymphoma with secondary <scp>CNS</scp> involvement. British Journal of Haematology, 2013, 162, 648-656.	2.5	29
315	Sex differences in the incidence of chronic myeloid leukemia. Radiation and Environmental Biophysics, 2014, 53, 55-63.	1.4	29
316	Haematopoietic cell transplants in Latin America. Bone Marrow Transplantation, 2016, 51, 898-905.	2.4	29
317	Cancer increases risk of in-hospital death from COVID-19 in persons <65 years and those not in complete remission. Leukemia, 2020, 34, 2384-2391.	7.2	29
318	Characterization of bcr gene products in hematopoietic cells. Oncogene, 1989, 4, 127-38.	5.9	29
319	The role of bone marrow transplantation following nuclear accidents. Bone Marrow Transplantation, 1987, 2, 1-6.	2.4	29
320	Leukemia of T-helper lymphocytes: Clinical and functional features. Leukemia Research, 1981, 5, 1-10.	0.8	28
321	Modeling minimal residual disease (MRD)-testing. Leukemia Research, 2003, 27, 293-300.	0.8	28
322	Comparison of Twin and Autologous Transplants for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2008, 14, 1118-1124.	2.0	28
323	How good are we at predicting the fate of someone with acute myeloid leukaemia?. Leukemia, 2017, 31, 1255-1258.	7.2	28
324	Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas. Bone Marrow Transplantation, 2018, 53, 457-460.	2.4	28

#	Article	IF	Citations
325	Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood, 1989, 74, 862-71.	1.4	28
326	POLYMORPHONUCLEAR LEUKOCYTE Fc RECEPTORS IN ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY (ADCC). Transplantation, 1976, 21, 524.	1.0	27
327	HOW CAN WE CURE LEUKAEMIA?. British Journal of Haematology, 1989, 72, 479-485.	2.5	27
328	Graft-versus-leukemia in chronic lymphocytic leukemia. Bone Marrow Transplantation, 2007, 39, 441-446.	2.4	27
329	Comparable Outcomes in Nonsecretory and Secretory Multiple Myeloma after Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 1134-1140.	2.0	27
330	Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure. Biology of Blood and Marrow Transplantation, 2012, 18, 1255-1264.	2.0	27
331	Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. Leukemia Research, 2017, 60, 18-23.	0.8	27
332	Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia. Clinical Cancer Research, 2020, 26, 3154-3161.	7.0	27
333	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia, 2020, 34, 3338-3347.	7.2	27
334	Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?. Frontiers in Immunology, 2021, 12, 706186.	4.8	27
335	Insights into the expression of ABH and Lewis antigens through human bone marrow transplantation. American Journal of Human Genetics, 1981, 33, 551-60.	6.2	27
336	Ph-chromosome positive acute leukemias and acute phase CML: One or two diseases? Two. Leukemia Research, 1990, 14, 295-297.	0.8	26
337	Are there roles for observational database studies and structured quantification of expert opinion to answer therapy controversies in transplants?. Bone Marrow Transplantation, 2009, 43, 435-446.	2.4	26
338	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. Biology of Blood and Marrow Transplantation, 2016, 22, 1056-1064.	2.0	26
339	Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2619-2630.	2.5	26
340	IL-22 Accelerates Thymus Regeneration via Stat3/Mcl-1 and Decreases Chronic Graft-versus-Host Disease in Mice after Allotransplants. Biology of Blood and Marrow Transplantation, 2019, 25, 1911-1919.	2.0	26
341	A comparison of human lymphoid cells in antibody-dependent cellular cytotoxicity (ADCC). Clinical Immunology and Immunopathology, 1975, 3, 377-384.	2.0	25
342	Multiple molecular abnormalities in Ph1chromosome positive acute lymphoblastic leukaemia. British Journal of Haematology, 1987, 67, 319-324.	2.5	25

#	Article	IF	Citations
343	Bone marrow autotransplantation. American Journal of Medicine, 1989, 86, 203-206.	1.5	25
344	Collective Biodosimetry as a Dosimetric â€œGold Standardâ€• Health Physics, 1997, 72, 390-396.	0.5	25
345	National Biometry Audit II. Eye, 2006, 20, 25-28.	2.1	25
346	Targeting High Dynamin-2 (DNM2) Expression by Restoring Ikaros Function in Acute Lymphoblastic Leukemia. Scientific Reports, 2016, 6, 38004.	3.3	25
347	Recent advances in the immunologic classification of leukemia. Seminars in Hematology, 1986, 23, 257-83.	3.4	25
348	Chronic myeloid leukemia. American Journal of Medicine, 1986, 80, 1137-1148.	1.5	24
349	Radiation Accidents and Nuclear Energy: Medical Consequences and Therapy. Annals of Internal Medicine, 1988, 109, 730.	3.9	24
350	JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms. Leukemia, 2013, 27, 1763-1767.	7.2	24
351	Use of the Functional Assessment of Cancer Therapyâ^'Anemia in Persons with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia. Clinical Therapeutics, 2014, 36, 560-566.	2.5	24
352	Should persons with acute myeloid leukemia have a transplant in first remission?. Leukemia, 2014, 28, 1949-1952.	7.2	24
353	Autotransplantation for leukemia and solid tumors. Transplantation Proceedings, 1978, 10, 177-84.	0.6	24
354	Are new conditioning regimens for transplants in acute myelogenous leukemia better?. Bone Marrow Transplantation, 1991, 7, 255-61.	2.4	24
355	Acute myeloid leukaemia: recent advances in therapy. Clinics in Haematology, 1986, 15, 781-810.	2.3	24
356	No increased mortality from donor or recipient hepatitis <scp>B</scp>â€•and/or hepatitis <scp>C</scp>â€•positive serostatus after relatedâ€•donor allogeneic hematopoietic cell transplantation. Transplant Infectious Disease, 2012, 14, 468-478.	1.7	23
357	Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. Bone Marrow Transplantation, 2015, 50, 1057-1062.	2.4	23
358	Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort. Biology of Blood and Marrow Transplantation, 2015, 21, 640-645.	2.0	23
359	Cysteine and glycine-rich protein 2 (CSRP2) transcript levels correlate with leukemia relapse and leukemia-free survival in adults with B-cell acute lymphoblastic leukemia and normal cytogenetics. Oncotarget, 2017, 8, 35984-36000.	1.8	23
360	B cell acute lymphoblastic leukemia (ALL) in donor cells following bone marrow transplantation for T cell ALL. Bone Marrow Transplantation, 1988, 3, 331-7.	2.4	23

#	Article	IF	Citations
361	Molecular biology of chronic myelogenous leukemia. Seminars in Hematology, 1988, 25, 35-48.	3.4	23
362	POTENTIAL UTILIZATION OF A NATIONAL HLA-TYPED DONOR POOL FOR BONE MARROW TRANSPLANTATION. Transplantation, 1986, 42, 54-57.	1.0	22
363	Oncogenes in chronic lymphocytic leukemia. Leukemia Research, 1988, 12, 89-92.	0.8	22
364	Autotransplantation in Lymphoma: Better Therapy or Healthier Patients?. Annals of Internal Medicine, 1991, 114, 1059-1060.	3.9	22
365	Genetically identical twin transplantation for chronic lymphocytic leukemia. Leukemia, 2007, 21, 2452-2455.	7.2	22
366	5â€²-Triphosphate siRNA targeting MDR1 reverses multi-drug resistance and activates RIG-I-induced immune-stimulatory and apoptotic effects against human myeloid leukaemia cells. Leukemia Research, 2017, 58, 23-30.	0.8	22
367	Use of molecularly-cloned haematopoietic growth factors in persons exposed to acute high-dose, high-dose rate whole-body ionizing radiations. Blood Reviews, 2021, 45, 100690.	5.7	22
368	Bone marrow transplantation for Diamond-Blackfan anemia. Bone Marrow Transplantation, 1995, 15, 55-8.	2.4	22
369	Chronic Leukemias: Oncogenes, Chromosomes, and Advances in Therapy. Annals of Internal Medicine, 1986, 104, 671.	3.9	21
370	Use of conditioned media in cell culture can mask cytogenetic abnormalities in acute leukemia. Cancer Genetics and Cytogenetics, 1990, 46, 107-113.	1.0	21
371	Multiple myeloma and chronic lymphocytic leukemia: Parallels and contrasts. American Journal of Medicine, 1992, 93, 443-450.	1.5	21
372	Autologous Hematopoietic Stem-Cell Transplantation for Children With Acute Myeloid Leukemia in First or Second Complete Remission: A Prognostic Factor Analysis. Journal of Clinical Oncology, 2004, 22, 3798-3804.	1.6	21
373	Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1549-1555.	2.5	21
374	Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. Blood Advances, 2018, 2, 1198-1206.	5.2	21
375	Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2398-2407.	2.0	21
376	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. Biology of Blood and Marrow Transplantation, 2019, 25, 270-278.	2.0	21
377	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 2020, 26, 472-479.	2.0	21
378	Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection. Leukemia, 2020, 34, 2704-2707.	7.2	21

#	Article	IF	Citations
379	Ethnic and geographic diversity of chronic lymphocytic leukaemia. Leukemia, 2021, 35, 433-439.	7.2	21
380	Prognostic impact of Epstein-Barr virus (EBV)-DNA copy number at diagnosis in chronic lymphocytic leukemia. Oncotarget, 2016, 7, 2135-2142.	1.8	21
381	Bone marrow transplantation in chronic myelogenous leukemia. Seminars in Hematology, 1988, 25, 74-80.	3.4	21
382	National Biometry Audit. Eye, 2004, 18, 63-66.	2.1	20
383	Pretransplantation Consolidation Chemotherapy Decreases Leukemia Relapse after Autologous Blood and Bone Marrow Transplants for Acute Myelogenous Leukemia in First Remission. Biology of Blood and Marrow Transplantation, 2006, 12, 204-216.	2.0	20
384	Therapy of acute myelogenous leukemia. Blood Reviews, 1992, 6, 15-25.	5.7	19
385	Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. Clinical Transplantation, 2000, 14, 32-41.	1.6	19
386	Risk Factors Affecting Outcome of Second HLA-Matched Sibling Donor Transplantations for Graft Failure in Severe Acquired Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2009, 15, 626-631.	2.0	19
387	Imatinib results in better outcomes than HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia. Leukemia, 2013, 27, 2410-2413.	7.2	19
388	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2017, 23, 269-277.	2.0	19
389	Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. Bone Marrow Transplantation, 2019, 54, 1354-1360.	2.4	19
390	Involvement of opioid peptides in the analgesic, immunosuppressive, and tumor-enhancing effects of stress. Psychopharmacology Bulletin, 1985, 21, 479-84.	0.0	19
391	Bone Marrow Transplantationâ€"1994: A Report from the International Bone Marrow Transplant Registry and the North American Autologous Bone Marrow Transplant Registry. Stem Cells and Development, 1994, 3, 95-102.	1.0	18
392	Outcomes of Human Leukocyte Antigenâ€"Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced-Intensity Conditioning Regimens. Biology of Blood and Marrow Transplantation, 2014, 20, 1390-1398.	2.0	18
393	A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes. Experimental Hematology and Oncology, 2015, 5, 12.	5.0	18
394	Bone Marrow Therapies for Chronic Heart Disease. Stem Cells, 2015, 33, 3212-3227.	3.2	18
395	Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2V617F or MPL mutations. Leukemia Research, 2015, 39, 510-514.	0.8	18
396	Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1013-1022.	2.5	18

#	Article	IF	Citations
397	Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much. Leukemia Research, 2017, 57, 109-111.	0.8	18
398	Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. Leukemia Research, 2017, 63, 34-40.	0.8	18
399	Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia. Haematologica, 2018, 103, 101-106.	3.5	18
400	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2019, 25, 683-688.	2.0	18
401	Mutation topography and risk stratification for de novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fmsâ€like tyrosine kinase 3 internal tandem duplication (FLT3â€ITD). British Journal of Haematology, 2020, 190, 274-283.	2.5	18
402	Prospects for achieving treatmentâ€free remission in chronic myeloid leukaemia. British Journal of Haematology, 2020, 190, 318-327.	2.5	18
403	Emergency response to radiological and nuclear accidents and incidents. British Journal of Haematology, 2021, 192, 968-972.	2.5	18
404	Acute lymphoblastic leukemia: recent advances in biology and therapy. Blood, 1989, 73, 2051-66.	1.4	18
405	Do androgens enhance the response to antithymocyte globulin in patients with aplastic anemia? A prospective randomized trial. Blood, 1985, 66, 184-8.	1.4	18
406	Analysis ofBCR-ABL mRNA in chronic myelogenous leukemia patients and identification of a newBCR-related sequence in human DNA. Genes Chromosomes and Cancer, 1989, 1, 172-179.	2.8	17
407	Graft versus leukemia. Immunologic Research, 1992, 11, 24-33.	2.9	17
408	The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. Haematologica, 2011, 96, 590-601.	3.5	17
409	Concise review: Bone marrow autotransplants for liver disease?. Stem Cells, 2013, 31, 2313-2329.	3.2	17
410	Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research. Biology of Blood and Marrow Transplantation, 2013, 19, 1102-1108.	2.0	17
411	Why is there so much therapy-related AML and MDS and so little therapy-related CML?. Leukemia Research, 2014, 38, 1162-1164.	0.8	17
412	Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis. OncoTargets and Therapy, 2015, 8, 1091.	2.0	17
413	Outcomes following autologous hematopoietic stem cell transplant for patients with relapsed Wilmsâ€™ tumor: a CIBMTR retrospective analysis. Bone Marrow Transplantation, 2017, 52, 1549-1555.	2.4	17
414	Allogeneic Transplantation for Relapsed WaldenstrÃ¶m Macroglobulinemia and Lymphoplasmacytic Lymphoma. Biology of Blood and Marrow Transplantation, 2017, 23, 60-66.	2.0	17

#	Article	IF	Citations
415	Direct adjusted survival and cumulative incidence curves for observational studies. Bone Marrow Transplantation, 2020, 55, 538-543.	2.4	17
416	Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19). Leukemia, 2021, 35, 1661-1670.	7.2	17
417	Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?. Leukemia, 2022, 36, 482-491.	7.2	17
418	Outcomes of rituximabâ€BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer, 2020, 126, 2279-2287.	4.1	17
419	An Immune Risk Score Predicts Survival of Patients with Acute Myeloid Leukemia Receiving Chemotherapy. Clinical Cancer Research, 2021, 27, 255-266.	7.0	17
420	Neutrophil Function in Bone Marrow Transplant Recipients. British Journal of Haematology, 1977, 35, 245-250.	2.5	16
421	Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis?. Leukemia Research, 2010, 34, 1119-1120.	0.8	16
422	Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia. Experimental Hematology, 2013, 41, 772-778.	0.4	16
423	Autologous GVHD?. Bone Marrow Transplantation, 2014, 49, 1349-1351.	2.4	16
424	Monosomal karyotype is an independent predictor of survival in patients with higherâ€risk myelodysplastic syndrome. American Journal of Hematology, 2014, 89, E163-8.	4.1	16
425	Correcting 2 more myths regarding transplants for AML in second remission. Blood, 2014, 123, 794-794.	1.4	16
426	BCL11A expression in acute myeloid leukemia. Leukemia Research, 2016, 41, 71-75.	0.8	16
427	Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis. Journal of Hematology and Oncology, 2017, 10, 99.	17.0	16
428	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2017, 23, 971-979.	2.0	16
429	Patientsâ€™ and hematologistsâ€™ concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2018, 144, 735-741.	2.5	16
430	Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, e145-e154.	2.0	16
431	A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS. Blood, 2011, 118, 115-115.	1.4	16
432	Chronic myelogenous leukemia--the unfolding saga. Leukemia, 1990, 4, 163-7.	7.2	16

#	Article	IF	Citations
433	What is the role of recombinant colony stimulating factors in bone marrow transplantation?. Bone Marrow Transplantation, 1990, 6, 79-87.	2.4	16
434	Case problems in bone marrow transplantation. I. Graft failure in aplastic anemia: its biology and treatment. Experimental Hematology, 1984, 12, 728-33.	0.4	16
435	Leukemia-Associated Antigens Detected by Heterologous Antisera 2. Journal of the National Cancer Institute, 1976, 56, 1217-1219.	6.3	15
436	Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute lymphoblastic leukemia in first remission. Leukemia Research, 1998, 22, 973-981.	0.8	15
437	Therapy-related AML: A slip of the lip can sink a ship. Leukemia Research, 2014, 38, 418-420.	0.8	15
438	Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients Age 70 Years and Older: A CIBMTR Study of Trends and Outcomes. Biology of Blood and Marrow Transplantation, 2016, 22, S68-S69.	2.0	15
439	Medical and policy considerations for nuclear and radiation accidents, incidents and terrorism. Current Opinion in Hematology, 2017, 24, 496-501.	2.5	15
440	Is there expert consensus on expert consensus?. Bone Marrow Transplantation, 2018, 53, 1055-1060.	2.4	15
441	G-CSF and GM-CSF Are Different. Which One Is Better for COVID-19?. Acta Haematologica, 2021, 144, 355-359.	1.4	15
442	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. Transplantation and Cellular Therapy, 2021, 27, 68.e1-68.e9.	1.2	15
443	A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. Blood, 2021, 137, 896-907.	1.4	15
444	High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia. Leukemia, 2021, 35, 2412-2415.	7.2	15
445	A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma. Leukemia, 2021, 35, 3212-3222.	7.2	15
446	PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I. Blood, 2019, 134, 1638-1638.	1.4	15
447	Autotransplants: now and in the future. Bone Marrow Transplantation, 1991, 7, 153-7.	2.4	15
448	BONE MARROW TRANSPLANTATION BETWEEN A HISTOCOMPATIBLE PARENT AND CHILD FOR ACUTE LEUKEMIA. Transplantation, 1978, 25, 88-90.	1.0	14
449	Is there really a specific graft-versus-leukaemia effect?. Bone Marrow Transplantation, 2016, 51, 1413-1415.	2.4	14
450	Are mild/moderate acquired idiopathic aplastic anaemia and low-risk myelodysplastic syndrome one or two diseases or both and how should it/they be treated?. Leukemia, 2016, 30, 2127-2130.	7.2	14

#	Article	IF	Citations
451	Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for I nternational B lood and M arrow T ransplant R esearch cohort analysis. Cancer, 2017, 123, 2035-2042.	4.1	14
452	Acute myeloid leukemia therapy and the chosen people. Leukemia, 2017, 31, 269-271.	7.2	14
453	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1875-1883.	2.0	14
454	Survival Trends in Infants Undergoing Allogeneic Hematopoietic Cell Transplant. JAMA Pediatrics, 2019, 173, e190081.	6.2	14
455	Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 2019, 54, 648-661.	2.4	14
456	Causal inference in randomized clinical trials. Bone Marrow Transplantation, 2020, 55, 4-8.	2.4	14
457	Comparison of outcomes of HCT in blast phase of BCR-ABL1â˜ MPN with de novo AML and with AML following MDS. Blood Advances, 2020, 4, 4748-4757.	5.2	14
458	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2020, 26, 2139-2146.	2.0	14
459	COVID-19 in Patients with Hematologic Disorders Undergoing Therapy: Perspective of a Large Referral Hematology Center in Rome. Acta Haematologica, 2020, 143, 574-582.	1.4	14
460	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Advances, 2020, 4, 2084-2094.	5.2	14
461	Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?. Leukemia, 2020, 34, 963-965.	7.2	14
462	Methotrexate therapy of T-cell large granular lymphocytic leukemia impact of STAT3 mutation. Oncotarget, 2016, 7, 61419-61425.	1.8	14
463	Prognostic value of whole-body SUVmax of nodal and extra-nodal lesions detected by 18F-FDG PET/CT in extra-nodal NK/T-cell lymphoma. Oncotarget, 2017, 8, 1737-1743.	1.8	14
464	Oncogenes and leukemia. Leukemia, 1990, 4, 138-60.	7.2	14
465	Phase I study of high-dose mitomycin with autologous bone marrow support. Cancer Treatment Reports, 1982, 66, 277-82.	0.5	14
466	Allogeneic bone marrow transplantation for leukemia. Current Opinion in Hematology, 1994, 1, 402-5.	2.5	14
467	Progress in bone marrow transplantation in man. Survey of Immunologic Research, 1982, 1, 40-66.	0.4	14
468	Cell Surface Antigens Detected on Mature and Leukemic Granulocytic Populations by Cytotoxicity Testing. Tissue Antigens, 1978, 12, 75-86.	1.0	13

#	Article	IF	Citations
469	Autoreactivity Between Lymphocytes and Thymus Cells in Myasthenia Gravis. Archives of Neurology, 1978, 35, 413-415.	4.5	13
470	IMMUNOGLOBULIN SYNTHESIS FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION IN MAN. Transplantation, 1979, 27, 212-213.	1.0	13
471	What is hybrid acute leukemia. Leukemia Research, 1989, 13, 725-728.	0.8	13
472	Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute myelogenous leukemia in 1st remission. Leukemia Research, 1999, 23, 709-718.	0.8	13
473	Providing Personalized Prognostic Information for Adult Leukemia Survivors. Biology of Blood and Marrow Transplantation, 2013, 19, 1600-1607.	2.0	13
474	Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative Human Leukocyte Antigenâ€“Identical Sibling Transplantations for Chronic Lymphocytic Leukemia?. Biology of Blood and Marrow Transplantation, 2014, 20, 421-424.	2.0	13
475	Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1776-1782.	2.0	13
476	TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia. Stem Cell Investigation, 2016, 3, 50-50.	3.0	13
477	Reduced frequency of circulating CD4+CD25brightCD127lowFOXP3+ regulatory T cells in primary myelofibrosis. Blood, 2016, 128, 1660-1662.	1.4	13
478	Maintenance of human haematopoietic stem and progenitor cells in vitro using a chemical cocktail. Cell Discovery, 2018, 4, 59.	6.7	13
479	Is there an epidemic of chronic lymphocytic leukaemia (CLL) in China?. Leukemia Research, 2018, 73, 16-20.	0.8	13
480	Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. Blood Advances, 2018, 2, 1022-1031.	5.2	13
481	Can we prevent or treat graft-versus-host disease with cellular-therapy?. Blood Reviews, 2020, 43, 100669.	5.7	13
482	Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 410-422.	1.2	13
483	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplantation, 2021, 56, 3068-3077.	2.4	13
484	Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy. Blood, 2018, 132, 790-790.	1.4	13
485	Approaches to leukemic relapse following bone marrow transplantation. Transplantation Proceedings, 1978, 10, 167-71.	0.6	13
486	Do chromosome abnormalities determine the type of acute leukemia that develops in CML?. Leukemia, 1990, 4, 65-8.	7.2	13

#	Article	IF	Citations
487	Immediate medical consequences of nuclear accidents. Lessons from Chernobyl. JAMA - Journal of the American Medical Association, 1987, 258, 625-8.	7.4	13
488	Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story. Blood Advances, 2022, 6, 2331-2333.	5.2	13
489	The Effect of Endotoxin on Circulating Lymphocytes in Normal Man. British Journal of Haematology, 1977, 36, 49-58.	2.5	12
490	Safety and tolerance of recombinant leukocyte A interferon in bone marrow transplant recipients. Antimicrobial Agents and Chemotherapy, 1983, 23, 846-851.	3.2	12
491	AUTOTRANSPLANTS IN ACUTE LEUKAEMIA. British Journal of Haematology, 1991, 78, 135-137.	2.5	12
492	Should people with hepatitis C virus infection receive a bone marrow transplant?. Bone Marrow Transplantation, 1997, 19, 97-99.	2.4	12
493	Utility of Single versus Tandem Autotransplants for Advanced Testes/Germ Cell Cancer: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. Biology of Blood and Marrow Transplantation, 2007, 13, 778-789.	2.0	12
494	MNSs Antigens Graft versus Host Disease Following Bone Marrow Transplantation. Tissue Antigens, 1980, 15, 212-215.	1.0	12
495	Generic Immunosuppressants in Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 285-290.	2.0	12
496	Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation. Biology of Blood and Marrow Transplantation, 2015, 21, 552-558.	2.0	12
497	Ionizing radiation exposures in treatments of solid neoplasms are not associated with subsequent increased risks of chronic lymphocytic leukemia. Leukemia Research, 2016, 43, 9-12.	0.8	12
498	Precision medicine in acute myeloid leukemia: Hope, hype or both?. Leukemia Research, 2016, 48, 73-77.	0.8	12
499	Phase-1/-2 study of pomalidomide in chronic GvHD. Bone Marrow Transplantation, 2016, 51, 612-614.	2.4	12
500	Chinese and Europeans with acute myeloid leukemia have discordant mutation topographies. Leukemia Research, 2018, 70, 8-12.	0.8	12
501	New drugs in AML: uses and abuses. Leukemia, 2018, 32, 1479-1481.	7.2	12
502	Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. Biology of Blood and Marrow Transplantation, 2019, 25, 1099-1106.	2.0	12
503	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Advances, 2019, 3, 1441-1449.	5.2	12
504	Perspective: SARS-CoV-2, COVID-19 and Haematologists. Acta Haematologica, 2021, 144, 117-121.	1.4	12

#	Article	IF	Citations
505	Pomalidomide Therapy in Myelofibrosis: 2-Year Follow-up of a Randomized Phase 2 Study.. Blood, 2009, 114, 1904-1904.	1.4	12
506	Interspecies variability in antibody-dependent cellular cytotoxicity (ADCC). Journal of Immunology, 1974, 113, 1145-50.	0.8	12
507	Changing causes of death in persons with haematological cancers 1975â€“2016. Leukemia, 2022, 36, 1850-1860.	7.2	12
508	A SENSITIVE IN VITRO MICROASSAY FOR DETECTING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY POSSIBLE ROLE IN MONITORING LYMPHOCYTE FUNCTION. Transplantation, 1974, 18, 27-30.	1.0	11
509	Immunologic classification of lymphoma and lymphoid leukemia. Blood Reviews, 1987, 1, 77-88.	5.7	11
510	Analysis of BCR/ABL Abnormalities in mRNA from 20-Year-Old Paraffin-Embedded Tissue for BCR/ABL Rearrangement by Polymerase Chain Reaction. Acta Haematologica, 1993, 90, 5-7.	1.4	11
511	Hypothesis: How do JAK2-inhibitors work in myelofibrosis. Leukemia Research, 2009, 33, 1156-1157.	0.8	11
512	Cytogenetic studies and their prognostic contribution in 565 <scp>C</scp>hinese patients with primary myelofibrosis. American Journal of Hematology, 2014, 89, 1043-1046.	4.1	11
513	What is the (p-) value of the P-value?. Leukemia, 2016, 30, 1965-1967.	7.2	11
514	Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation. Chinese Journal of Cancer, 2016, 35, 46.	4.9	11
515	BCL11A expression in acute phase chronic myeloid leukemia. Leukemia Research, 2016, 47, 88-92.	0.8	11
516	Therapy of older persons with acute myeloid leukaemia. Leukemia Research, 2017, 60, 1-10.	0.8	11
517	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biology of Blood and Marrow Transplantation, 2018, 24, 2443-2449.	2.0	11
518	Predicting the outcome of patients with chronic lymphocytic leukemia: Progress and uncertainty. Cancer, 2019, 125, 3699-3705.	4.1	11
519	DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia. British Journal of Haematology, 2020, 190, 67-78.	2.5	11
520	Therapy of posttransplant poor graft function with eltrombopag. Bone Marrow Transplantation, 2021, 56, 4-6.	2.4	11
521	Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?. Blood Reviews, 2021, 46, 100742.	5.7	11
522	Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors. Leukemia, 2021, 35, 2199-2204.	7.2	11

#	Article	IF	Citations
523	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplantation and Cellular Therapy, 2021, 27, 921.e1-921.e10.	1.2	11
524	Is there a T-cell form of chronic lymphocytic leukemia?. Leukemia, 1992, 6, 867-8.	7.2	11
525	Recipient immune-competent T lymphocytes can survive intensive conditioning for bone marrow transplantation. Blood, 1986, 68, 954-6.	1.4	11
526	Analysis of bone marrow transplantation data in man. Bone Marrow Transplantation, 1986, 1, 3-9.	2.4	11
527	A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy. Leukemia, 2022, 36, 1336-1342.	7.2	11
528	AGE OF ONSET AND TYPE OF LEUKAEMIA. Lancet, The, 1989, 334, 789-791.	13.7	10
529	Autotransplants in leukemia: Current state, future progress. Leukemia Research, 1991, 15, 781-784.	0.8	10
530	High-Dose Chemotherapy with Blood or Bone Marrow Transplants for Rhabdomyosarcoma. Biology of Blood and Marrow Transplantation, 2010, 16, 525-532.	2.0	10
531	If the unlikely becomes likely: Medical response to nuclear accidents. Bulletin of the Atomic Scientists, 2011, 67, 10-18.	0.6	10
532	Who is the best alternative allotransplant donor?. Bone Marrow Transplantation, 2015, 50, S40-S42.	2.4	10
533	The big freeze may be over: a contracting universe for cryopreservation?. Bone Marrow Transplantation, 2018, 53, 947-948.	2.4	10
534	Are We Prepared for Nuclear Terrorism?. New England Journal of Medicine, 2018, 378, 2447-2450.	27.0	10
535	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clinical Cancer Research, 2019, 25, 5143-5155.	7.0	10
536	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1744-1755.	2.0	10
537	Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 480-487.	2.0	10
538	Being certain even when youâ€™re wrong: heuristics and thin slicing in haematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 1223-1226.	2.4	10
539	Therapy decisions in leukemia. Bone Marrow Transplantation, 1992, 9, 5-10.	2.4	10
540	Bone marrow transplantation for acute myelogenous leukemia. Factors associated with early mortality. JAMA - Journal of the American Medical Association, 1983, 249, 1166-75.	7.4	10

#	Article	IF	Citations
541	The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica, 2023, 108, 150-160.	3.5	10
542	SERUM INHIBITORS OF IN VITRO HEMATOPOIESIS AND GRAFT OUTCOME IN BONE MARROW TRANSPLANTATION FOR APLASTIC ANEMIA. Transplantation, 1980, 29, 223-226.	1.0	9
543	Trisomy 12 in Burkitt-like lymphoma associated with acquired immunodeficiency syndrome. Cancer Genetics and Cytogenetics, 1987, 29, 245-251.	1.0	9
544	Bone Marrow Transplantation: Its Biology and Role as Treatment for Acute and Chronic Leukemias. Annals of the New York Academy of Sciences, 1987, 511, 447-458.	3.8	9
545	Are some cases of acute leukemia with t(8;21) hybrid leukemias?. Cancer Genetics and Cytogenetics, 1990, 49, 177-184.	1.0	9
546	Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in chronic myelogenous leukemia in chronic phase. Leukemia Research, 1999, 23, 817-826.	0.8	9
547	Closure of cyclodialysis cleft using diode laser. Eye, 2003, 17, 527-528.	2.1	9
548	Serum Ferritin Is an Independent Prognostic Factor in Chinese with Myelodysplastic Syndromes Classified as IPSS Intermediate-1. Acta Haematologica, 2013, 129, 243-250.	1.4	9
549	Measureable residual disease (MRD): much ado about nothing?. Bone Marrow Transplantation, 2015, 50, 163-164.	2.4	9
550	Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure. Biology of Blood and Marrow Transplantation, 2015, 21, 1790-1795.	2.0	9
551	Therapy-free remission in chronic myeloid leukemia: possible mechanism. Expert Review of Hematology, 2018, 11, 269-272.	2.2	9
552	Recent advances in the genomics and therapy of BCR/ABL1 -positive and -negative chronic myeloproliferative neoplasms. Leukemia Research, 2018, 67, 67-74.	0.8	9
553	Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide. Leukemia, 2021, 35, 1197-1202.	7.2	9
554	Is G-CSF Dangerous in COVID-19: Why Not Use GM-CSF?. Acta Haematologica, 2021, 144, 350-351.	1.4	9
555	A predictive score for progression of COVID-19 in hospitalized persons: a cohort study. Npj Primary Care Respiratory Medicine, 2021, 31, 33.	2.6	9
556	RBC distribution width predicts thrombosis risk in polycythemia vera. Leukemia, 2022, 36, 566-568.	7.2	9
557	Allogeneic bone marrow transplantation for 144 patients with severe aplastic anemia. JAMA - Journal of the American Medical Association, 1981, 245, 1132-9.	7.4	9
558	MYASTHENIA GRAVIS AND POLYMYOSITIS IN A DOG FOLLOWING FETAL HEMATOPOIETIC CELL TRANSPLANTATION. Transplantation, 1986, 41, 21-25.	1.0	8

#	Article	IF	Citations
559	Cord-Blood-Cell Transplantation â€" A Real Sleeper?. New England Journal of Medicine, 1995, 332, 392-395.	27.0	8
560	â€˜A rose by any other name would smell as sweetâ€™, or would it?. Bone Marrow Transplantation, 2013, 48, 881-883.	2.4	8
561	First use of myeloid colony-stimulating factors in humans. Bone Marrow Transplantation, 2013, 48, 1358-1358.	2.4	8
562	Engraftment syndrome, the Emperorâ€™s new clothes and the artist formerly known as prince. Bone Marrow Transplantation, 2015, 50, 483-484.	2.4	8
563	Early and late graft-failure after transplants. Bone Marrow Transplantation, 2016, 51, 182-183.	2.4	8
564	Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?. Leukemia, 2019, 33, 588-596.	7.2	8
565	Prognostic impact of red blood cell distribution width in myelodysplastic syndromes. British Journal of Haematology, 2019, 186, 352-355.	2.5	8
566	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. British Journal of Haematology, 2020, 191, 442-452.	2.5	8
567	Impact of stopping therapy during the SARS-CoV-2 pandemic in persons with lymphoma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1469-1479.	2.5	8
568	Significance of HLA and non-HLA antigens in bone marrow transplantation. Transplantation Proceedings, 1978, 10, 43-6.	0.6	8
569	Current status of bone marrow transplantation in acute leukemia. Transplantation Proceedings, 1979, 11, 1920-3.	0.6	8
570	Autologous bone marrow transplantation in patients with cancer. JAMA - Journal of the American Medical Association, 1980, 243, 540-2.	7.4	8
571	Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia. Leukemia, 2022, 36, 1227-1236.	7.2	8
572	A SENSITIVE METHOD FOR DETECTING ANTIBODIES IN HUMAN SERA USED FOR TISSUE TYPING. Transplantation, 1974, 18, 180-185.	1.0	7
573	ABSENCE OF SPECIFIC MIXED LEUKOCYTE CULTURE REACTIVITY DURING GRAFT-VERSUS-HOST DISEASE AND FOLLOWING BONE MARROW TRANSPLANT REJECTION. Transplantation, 1976, 22, 474-477.	1.0	7
574	Relationship Between Leukemia Antigens and Stimulation in Mixed Leukocyte Culture: Brief Communication2. Journal of the National Cancer Institute, 1977, 59, 95-98.	6.3	7
575	Immunity to human haematopoietic stem cells. Nature, 1979, 281, 220-222.	27.8	7
576	Plasma cell leukemia with iga paraproteinemia and hyperviscosity. American Journal of Hematology, 1988, 28, 113-115.	4.1	7

#	Article	IF	Citations
577	Intravenous immunoglobulin in bone marrow transplantation. Cancer, 1991, 68, 1451-1453.	4.1	7
578	Survival of patients with chronic myelogenous leukaemia relapsing after bone marrow transplantation: comparison with patients receiving conventional chemotherapy. British Journal of Haematology, 1997, 99, 23-29.	2.5	7
579	Delphi-Panel Analysis of Appropriateness of High-Dose Chemotherapy and Blood Cell or Bone Marrow Autotransplants in Diffuse Large-Cell Lymphoma. Leukemia and Lymphoma, 1998, 32, 139-149.	1.3	7
580	Delphi-Panel Analysis of Appropriateness of High-Dose Therapy and Bone Marrow Autotransplants in Newly Diagnosed Multiple Myeloma. Leukemia and Lymphoma, 1999, 33, 511-519.	1.3	7
581	Communicating cancer risk from radiation exposures: nuclear accidents, total body radiation and diagnostic procedures. Bone Marrow Transplantation, 2013, 48, 2-3.	2.4	7
582	Low frequency of mutations in Chinese with acute myeloid leukemia: Different disease or different aetiology?. Leukemia Research, 2015, 39, 646-648.	0.8	7
583	Colony-forming unit cell (CFU-C) assays at diagnosis: CFU-G/M cluster predicts overall survival in myelodysplastic syndrome patients independently of IPSS-R. Oncotarget, 2016, 7, 68023-68032.	1.8	7
584	The different prognostic impact of typeâ€1 or typeâ€1 like and typeâ€2 or typeâ€2 like CALR mutations in patients with primary myelofibrosis. American Journal of Hematology, 2016, 91, E320-1.	4.1	7
585	Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 945-955.	2.0	7
586	New study-designs to address the clinical complexity of acute myeloid leukemia. Leukemia, 2019, 33, 567-569.	7.2	7
587	Determine safety of outpatient chemotherapy and autotransplants using refrigerated, nonâ€frozen grafts in persons with multiple sclerosis. Clinical Transplantation, 2019, 33, e13567.	1.6	7
588	Variables associated with patient-reported symptoms in persons with chronic phase chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Medicine (United States), 2019, 98, e18079.	1.0	7
589	Microtransplantation for Acute Myeloid Leukemia. JAMA Oncology, 2020, 6, 1614.	7.1	7
590	Is cancer latency an outdated concept? Lessons from chronic myeloid leukemia. Leukemia, 2020, 34, 2279-2284.	7.2	7
591	Plasma sIL-2RÎ± levels are associated with disease progression in myelofibrosis with JAK2V617F but not CALR mutation. Leukemia Research, 2020, 90, 106319.	0.8	7
592	Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis. Leukemia, 2021, 35, 468-475.	7.2	7
593	Deoxycytidine Kinase (DCK) Mutations in Human Acute Myeloid Leukemia Resistant to Cytarabine. Acta Haematologica, 2021, 144, 534-541.	1.4	7
594	A prognostic immune risk score for diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2021, 194, 111-119.	2.5	7

#	Article	IF	Citations
595	Clonal Megakaryocyte Dysplasia with Normal Blood Values Is a Distinct Myeloproliferative Neoplasm. Acta Haematologica, 2022, 145, 30-37.	1.4	7
596	Chronic lymphocytic leukemia in China. Chinese Medical Journal, 2022, 135, 883-886.	2.3	7
597	Bone marrow transplantation in acute leukemia using intensive chemoradiotherapy (SCARI--UCLA). Transplantation Proceedings, 1976, 8, 611-6.	0.6	7
598	Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s. JAMA - Journal of the American Medical Association, 1992, 268, 607-12.	7.4	7
599	Is there a role for autotransplants in acute leukemia?. Bone Marrow Transplantation, 1989, 4, 217-9.	2.4	7
600	New and evolving concepts in leukemia. Leukemia, 1988, 2, 704-7.	7.2	7
601	Current status of bone marrow transplantation in humans: report from the International Bone Marrow Transplant Registry. Natural Immunity and Cell Growth Regulation, 1988, 7, 334-50.	0.2	7
602	Early leukemic recurrence of non-Hodgkin lymphoma after high-dose anti-neoplastic therapy with autologous marrow rescue. Bone Marrow Transplantation, 1987, 1, 373-8.	2.4	7
603	Transplantation of ABH incompatible bone marrow: gravity sedimentation of donor marrow. British Journal of Haematology, 1984, 57, 155-62.	2.5	7
604	Acute myelogenous leukemia following radiation therapy and chemotherapy for osteogenic sarcoma. Cancer Treatment Reports, 1984, 68, 909-11.	0.5	7
605	Is transplantation in first remission AML more effective than in advanced leukemia?. Leukemia Research, 1989, 13, 1035-1038.	0.8	6
606	Hybrid leukemia and the 5q-abnormality. Leukemia Research, 1991, 15, 351-356.	0.8	6
607	Croatia: Civilian hospitals as military targets. Lancet, The, 1992, 339, 48.	13.7	6
608	High Incidence of Conservative RAS Mutations in Acute Myeloid Leukemia. Acta Haematologica, 1994, 92, 123-125.	1.4	6
609	How important is hepatitis C virus (HCV)-infection in persons with acute leukemia?. Leukemia Research, 1997, 21, 785-788.	0.8	6
610	How Helpful Are Meta-Analyses in Determining the Best Therapy of Blood Diseases?. Acta Haematologica, 2011, 125, 91-101.	1.4	6
611	RBC-transfusion guidelines update. Leukemia Research, 2012, 36, 659-660.	0.8	6
612	Treating Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors. Acta Haematologica, 2013, 130, 192-195.	1.4	6

#	Article	IF	Citations
613	Prognostic impact of splenomegaly on survival of Chinese with primary myelofibrosis. Leukemia Research, 2014, 38, 1207-1211.	0.8	6
614	WHO HAS THERAPY-RELATED AML?. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017025.	1.3	6
615	What is the P-value anyway?. Bone Marrow Transplantation, 2016, 51, 1439-1440.	2.4	6
616	Is Having Clonal Cytogenetic Abnormalities the Same as Having Leukaemia?. Acta Haematologica, 2016, 135, 39-42.	1.4	6
617	Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia?. Haematologica, 2019, 104, 862-864.	3.5	6
618	MÃ©lange intÃ©ressante: COVID-19, autologous transplants and multiple sclerosis. Hematology, 2020, 25, 320-320.	1.5	6
619	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 2108-2117.	2.4	6
620	Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation. Acta Haematologica, 2022, 145, 54-62.	1.4	6
621	Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera. Blood Cancer Journal, 2021, 11, 154.	6.2	6
622	STAT3 and STAT5B mutations have unique distribution in T-cell large granular lymphocyte proliferations and advanced myeloid neoplasms. Leukemia and Lymphoma, 2021, 62, 1506-1509.	1.3	6
623	Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response. Blood, 2013, 122, 4067-4067.	1.4	6
624	Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). Blood, 2013, 122, 4088-4088.	1.4	6
625	PF-114 in Patients Failing Prior Tyrosine Kinase-Inhibitor Therapy Including BCR::ABL1T315I. Blood, 2021, 138, 1482-1482.	1.4	6
626	Detection of non-HLA antibodies in bone marrow transplant recipients. Transplantation Proceedings, 1978, 10, 963-4.	0.6	6
627	What determines who develops graft-versus-host disease: the graft or the host (or both)?. Bone Marrow Transplantation, 1992, 10, 99-102.	2.4	6
628	Bone marrow transplants for chronic lymphocytic leukaemia. Leukemia, 1992, 6, 619-22.	7.2	6
629	Staging and therapy of chronic lymphocytic leukemia. Seminars in Hematology, 1987, 24, 264-74.	3.4	6
630	Treatment of aplastic anemia: results with bone marrow transplantation, antithymocyte globulin, and a monoclonal anti-T cell antibody. Progress in Clinical and Biological Research, 1984, 148, 227-38.	0.2	6

#	Article	IF	Citations
631	Co-variates associated with outcomes of tyrosine kinase-inhibitor therapy in persons with chronic myeloid leukaemia initially presenting in accelerated phase. Leukemia, 2022, 36, 1818-1824.	7.2	6
632	BONE MARROW TRANSPLANTATION BETWEEN MIXED LYMPHOCYTE CULTURE-REACTIVE INDIVIDUALS. Transplantation, 1975, 20, 194-197.	1.0	5
633	Hematopoietic engraftment following transplantation of bone marrow cells carrying a Philadelphia (Phâ€²)â€like chromosome. American Journal of Hematology, 1977, 3, 137-142.	4.1	5
634	Experience with incompatible maternal donors for bone marrow transplantation. Blut, 1977, 34, 1-9.	1.2	5
635	Histiocytic lymphoma following resolution of sarcoidosis. Medical and Pediatric Oncology, 1981, 9, 325-331.	1.0	5
636	EVALUATION OF ANTITHYMOCYTE GLOBULIN FOR HUMAN BONE MARROW TRANSPLANTATION. Transplantation, 1982, 33, 625-630.	1.0	5
637	Amsa: A phase II trial in resistant and recurrent acute myelogenous leukemia. Medical and Pediatric Oncology, 1984, 12, 178-179.	1.0	5
638	Dose â€"Response effects of 4-hydroperoxycyclophosphamide on human T and B cell function in vitro. International Journal of Immunopharmacology, 1985, 7, 555-560.	1.1	5
639	Bone marrow transplantation in patients with leukaemia previously transfused with blood products from family members. British Journal of Haematology, 1987, 67, 67-70.	2.5	5
640	Oncogenes in Human Leukemias. Cancer Investigation, 1988, 6, 305-316.	1.3	5
641	Do different therapies of AML produce different outcomes?. Leukemia Research, 1990, 14, 207-208.	0.8	5
642	Is remission in acute myelogenous leukemia re-establishing preleukemia?. Leukemia Research, 1990, 14, 825-829.	0.8	5
643	Detecting minimal residual leukemia. Cancer Genetics and Cytogenetics, 1991, 52, 19-26.	1.0	5
644	Where does transformation occur in acute leukemia?. Leukemia Research, 1991, 15, 1183-1189.	0.8	5
645	BONE MARROW TRANSPLANTATION IN LEUKEMIA. Stem Cells and Development, 1994, 3, 235-238.	1.0	5
646	Are myelodysplastic syndromes and acute myeloid leukemia one disease?. Leukemia Research, 2009, 33, 351-354.	0.8	5
647	Markov model of CLL transplants. Bone Marrow Transplantation, 2012, 47, 1145-1146.	2.4	5
648	One or two umbilical cord blood cell units? Caveat emptor. Bone Marrow Transplantation, 2017, 52, 341-343.	2.4	5

#	Article	IF	Citations
649	Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation. Journal of Cancer, 2017, 8, 1009-1017.	2.5	5
650	Managing myeloproliferative neoplasms evidence based on the ELN treatment recommendations 2018. Leukemia, 2018, 32, 1055-1056.	7.2	5
651	Protease nexin-1 prevents growth of human B cell lymphoma via inhibition of sonic hedgehog signaling. Blood Cancer Journal, 2018, 8, 24.	6.2	5
652	What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias?. Current Hematologic Malignancy Reports, 2019, 14, 477-479.	2.3	5
653	A SAS macro for estimating direct adjusted survival functions for time-to-event data with or without left truncation. Bone Marrow Transplantation, 2022, 57, 6-10.	2.4	5
654	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances, 2022, 6, 828-847.	5.2	5
655	The state of haematopoietic cells transplantation in Latin America. Lancet Haematology,the, 2021, 8, e20-e21.	4.6	5
656	Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Transplantation and Cellular Therapy, 2022, 28, 335.e1-335.e17.	1.2	5
657	Number of HLA-Mismatched Eplets Is Not Associated with Major Outcomes in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: A Center for International Blood and Marrow Transplant Research Study. Transplantation and Cellular Therapy, 2022, 28, 107.e1-107.e8.	1.2	5
658	Clinical trials: design, endpoints and interpretation of outcomes. Bone Marrow Transplantation, 2022, 57, 338-342.	2.4	5
659	Further experience with infections in bone marrow transplant recipients. Transplantation Proceedings, 1978, 10, 247-54.	0.6	5
660	Radiation accidents: primum non nocere. Bone Marrow Transplantation, 1993, 11, 421-4.	2.4	5
661	Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study. Hematological Oncology, 2022, 40, 787-795.	1.7	5
662	Treatment of Acute Myelogenous Leukemia in Older Patients. New England Journal of Medicine, 1981, 305, 1470-1470.	27.0	4
663	Acute transformation of chronic lymphocytic leukemia. Medical and Pediatric Oncology, 1984, 12, 318-321.	1.0	4
664	Response to vriesendorp et al.. International Journal of Radiation Oncology Biology Physics, 1991, 20, 645-646.	0.8	4
665	A Critical Reappraisal of Gastrointestinal Complications of Allogeneic Bone Marrow Transplantation. Cell Transplantation, 1992, 1, 265-269.	2.5	4
666	8 Intensive therapy of chronic lymphocytic leukaemia. Best Practice and Research: Clinical Haematology, 1993, 6, 879-885.	1.1	4

#	Article	IF	Citations
667	Comparison of chemotherapy and bone marrow transplants using two independent clinical databases. Journal of Clinical Epidemiology, 1994, 47, 1119-1126.	5.0	4
668	Therapy of acute myelogenous leukemia: Understanding the question, understanding the answer. Leukemia Research, 1997, 21, 3-8.	0.8	4
669	Bone marrow fibrosis in myeloproliferative neoplasms-associated myelofibrosis: Deconstructing a myth?. Leukemia Research, 2011, 35, 563-565.	0.8	4
670	Autotransplantations Without Cryopreservation. Journal of Global Oncology, 2018, 4, 1-1.	0.5	4
671	The prognostic role of HBV infection in chronic lymphocytic leukemia. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1309-1315.	2.5	4
672	Refining AML outcome prediction. Leukemia, 2019, 33, 283-284.	7.2	4
673	Statistical analyses of clinical trials in haematopoietic cell transplantation or why there is a strong correlation between people drowning after falling out of a fishing boat and marriage rate in Kentucky. Bone Marrow Transplantation, 2020, 55, 1-3.	2.4	4
674	Mutational features of myelodysplastic syndromes with Auer rods reveal them are more akin to acute myeloid leukemia. British Journal of Haematology, 2020, 188, 796-800.	2.5	4
675	Chronic lymphocytic leukemia in 2020: a surfeit of riches?. Leukemia, 2020, 34, 1979-1983.	7.2	4
676	Point: Is there a best duration of deep molecular response to achieve therapyâ€free remission in chronic myeloid leukaemia?. British Journal of Haematology, 2021, 192, 22-23.	2.5	4
677	How Do We Manage Hematopoietic Cell Transplant during the SARS-CoV-2 Pandemic?. Acta Haematologica, 2021, 144, 500-507.	1.4	4
678	COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021034.	1.3	4
679	The paradox of haematopoietic cell transplant in Latin America. Bone Marrow Transplantation, 2021, 56, 2382-2388.	2.4	4
680	Role of molecularly-cloned hematopoietic growth factors after acute high-dose radiation exposures. Journal of Radiological Protection, 2021, 41, S478-S489.	1.1	4
681	Mental Health in Persons With Chronic Myeloid Leukemia During the SARS-CoV-2 Pandemic: The Need for Increased Access to Health Care Services. Frontiers in Psychiatry, 2021, 12, 679932.	2.6	4
682	Toward the Cure of Acute Lymphoblastic Leukemia in Children in China. JCO Global Oncology, 2021, 7, 1176-1186.	1.8	4
683	Granulocyte transfusions in haematopoietic cell transplants and leukaemia: the phoenix or beating a dead horse?. Bone Marrow Transplantation, 2021, 56, 2046-2049.	2.4	4
684	Improving prediction accuracy in acute myeloid leukaemia: micro-environment, immune and metabolic models. Leukemia, 2021, 35, 3073-3077.	7.2	4

#	Article	IF	Citations
685	Clinical Relevance of VEGFA (rs3025039) +936 C>T Polymorphism in Primary Myelofibrosis: Susceptibility, Clinical Co-Variates, and Outcomes. Genes, 2021, 12, 1271.	2.4	4
686	Is race important in genomic classification of hematological neoplasms?. Hematological Oncology, 2021, 39, 728-732.	1.7	4
687	Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?. Leukemia, 2021, 35, 3364-3370.	7.2	4
688	Pomalidomide Therapy in Anemic Patients with Myelofibrosis: Results from a Phase-2 Randomized Multicenter Study. Blood, 2008, 112, 663-663.	1.4	4
689	Age and Cost Are Associated with Patient Preference for Stopping Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. Blood, 2015, 126, 1585-1585.	1.4	4
690	Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone Marrow Transplantation, 2022, 57, 31-37.	2.4	4
691	Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients. Blood, 2012, 120, 1726-1726.	1.4	4
692	Correlations between Mutations in Cancer-Related Genes, Therapy Responses and Outcomes of the 3 rd Generation Tyrosine Kinase-Inhibitor (TKI) in Persons with Chronic Myeloid Leukemia Failing Prior TKI-Therapy. Blood, 2021, 138, 308-308.	1.4	4
693	Fulminant hepatic failure following bone marrow transplantation for hepatitis-associated aplastic anemia. Bone Marrow Transplantation, 1990, 5, 57-60.	2.4	4
694	Daunorubicin or doxorubicin in acute myelogenous leukemia?. Leukemia, 1988, 2, 209-10.	7.2	4
695	Abnormal T-lymphocyte colonies (CFU-TL) following bone marrow transplantation. Experimental Hematology, 1986, 14, 1049-55.	0.4	4
696	Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy. Leukemia, 2022, 36, 2042-2049.	7.2	4
697	Human B-lymphocyte antigens expressed by lymphocytic and myelocytic leukemia cells: Lymphocyte-dependent antibody studies with rabbit antisera. Leukemia Research, 1977, 1, 13-18.	0.8	3
698	DETECTION OF NON-HLA ANTIGENS. Transplantation, 1979, 28, 207-211.	1.0	3
699	Chernobyl: Answers Slipping Away. Bulletin of the Atomic Scientists, 1990, 46, 19-23.	0.6	3
700	Can Long-Term Bone Marrow Culture Eliminate Leukemia Cells?. Leukemia and Lymphoma, 1990, 3, 87-91.	1.3	3
701	USSR: Follow-up after Cherriobyl. Lancet, The, 1990, 335, 401-402.	13.7	3
702	Are we curing acute myelogenous leukemia?. Leukemia Research, 1993, 17, 1071-1072.	0.8	3

#	Article	IF	Citations
703	Sensitization against Nonâ€HLA Antigens Following Bone Marrow Graft Rejection. Tissue Antigens, 1977, 9, 209-219.	1.0	3
704	E Donnall Thomas (1920â€“2012). Leukemia, 2013, 27, 259-259.	7.2	3
705	Dirk Willem van Bekkum: a pioneer in haematology, transplantation and radiobiology (1925â€“2015). Leukemia, 2015, 29, 2275-2276.	7.2	3
706	Transmission of CML or of t(9; 22) and BCR/ABL? They are not the same. Bone Marrow Transplantation, 2015, 50, 1582-1582.	2.4	3
707	Chronic myeloid leukemia: Two mysteries. Leukemia Research, 2019, 79, 3-5.	0.8	3
708	Will immune therapy cure acute myeloid leukemia?. Blood Science, 2019, 1, 2-3.	0.9	3
709	Can a disease be conquered by extensive publications, reading guidelines and interminable meetings?. Leukemia, 2020, 34, 1977-1978.	7.2	3
710	New cancer therapies. Are haematopoietic cell transplants a dead duck?. Bone Marrow Transplantation, 2021, 56, 1086-1089.	2.4	3
711	Emil J Freireich and Baruch Spinoza: birds of a feather?. Leukemia, 2021, 35, 1812-1813.	7.2	3
712	Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia. Journal of Cancer Research and Clinical Oncology, 2022, 148, 449-459.	2.5	3
713	Phase-1 Study of ZIO-101: A New Organic Arsenic Active in Acute Myelogenous Leukemia (AML) and Multiple Myeloma (MM).. Blood, 2006, 108, 1966-1966.	1.4	3
714	Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs. Blood, 2015, 126, 4080-4080.	1.4	3
715	Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia. Blood, 2016, 128, 679-679.	1.4	3
716	Primary myelofibrosis: rs2010963 VEGFA polymorphism favors a prefibrotic phenotype and is associated with higher risk of thrombosis. Leukemia Research, 2021, 111, 106730.	0.8	3
717	Bone marrow transplantation for thalassaemia--a preliminary report from the International Bone Marrow Transplant Registry. Progress in Clinical and Biological Research, 1989, 309, 173-85.	0.2	3
718	New insights into a chronic lymphocytic leukemia. Leukemia, 1987, 1, 677-9.	7.2	3
719	Immunomodulating effects in vitro of interleukin-2 and interferon-gamma on human blood and bone marrow mononuclear cells. Natural Immunity and Cell Growth Regulation, 1988, 7, 13-30.	0.2	3
720	The bcr gene is joined to c-abl in Ph1 chromosome negative chronic myelogenous leukemia. Oncogene Research, 1988, 2, 167-75.	1.2	3

#	Article	IF	Citations
721	Bone marrow modulaton of spontaneous killer cellular cytotoxicity (SKCC) induction. Journal of Clinical & Laboratory Immunology, 1980, 4, 1-6.	0.1	3
722	Myeloid colony-forming cell kinetics in man. Experimental Hematology, 1980, 8, 271-7.	0.4	3
723	What's new in blood progenitor cell autotransplants?. Bone Marrow Transplantation, 1994, 14, 343-6.	2.4	3
724	Safety and efficacy of a humanized <scp>CD19</scp> chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia. American Journal of Hematology, 2022, 97, 711-718.	4.1	3
725	Lymphoma Nomenclature â€•What's in a name?. British Journal of Haematology, 2022, 197, 539-543.	2.5	3
726	Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. Transplantation and Cellular Therapy, 2022, 28, 712.e1-712.e8.	1.2	3
727	EFFECT OF ANTITHYMOCYTE GLOBULIN ON HISTOCOMPATIBILITY ANTIGEN RECOGNITION IN MAN. Transplantation, 1981, 31, 101-105.	1.0	2
728	Will more intensive chemotherapy of leukemia increase cures?. Leukemia Research, 1991, 15, 185-187.	0.8	2
729	Syngeneic hematopoietic stem cell transplantation for women with metastatic breast cancer. Bone Marrow Transplantation, 2003, 32, 151-155.	2.4	2
730	Professor John M Goldman, 1938â€“2013: Gentleman and Scholar. Leukemia, 2014, 28, 1175-1176.	7.2	2
731	Reply to Passamonti et al: ruxolitinib and survival improvement in patients with myelofibrosis. Leukemia, 2015, 29, 740-740.	7.2	2
732	Thirty years of Bone Marrow Transplantation. Bone Marrow Transplantation, 2016, 51, 1411-1412.	2.4	2
733	Study Limitations in HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia. JAMA Oncology, 2018, 4, 891.	7.1	2
734	Response to â€œQuestions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisionsâ€•by Heidel et al.. Leukemia, 2018, 32, 2727-2728.	7.2	2
735	Does a durian smell like a rose? The dangers of jargon. Bone Marrow Transplantation, 2020, 55, 280-282.	2.4	2
736	The not so new history of storing bone marrow. Bone Marrow Transplantation, 2020, 55, 1694-1696.	2.4	2
737	Perspective: Cell therapy, SARSâ€CoVâ€2, COVIDâ€19, and James Lind. Advances in Cell and Gene Therapy, 2020, 3, e88.	0.9	2
738	A Haematologistâ€™s Guide to Coronavirus Disease 2019: Encyclopaedia or Doorstop?. Acta Haematologica, 2021, 144, 8-9.	1.4	2

#	Article	IF	Citations
739	Correction of murine sickle cell disease by allogeneic haematopoietic cell transplantation with anti-3rd party veto cells. Bone Marrow Transplantation, 2021, 56, 1818-1827.	2.4	2
740	Is there a role for haematopoietic cell transplants after radiation and nuclear accidents?. Journal of Radiological Protection, 2021, 41, R43-R49.	1.1	2
741	Prior Therapy with Rituximab Correlates with Less Acute Graft-Versus-Host Disease and Better Survival in B-Cell Lymphoma Patients Who Received Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).. Blood, 2007, 110, 1063-1063.	1.4	2
742	Phase-2 Study of Pomalidomide in Advanced Corticosteroid-Resistant Chronic Graft-Versus-Host Disease (cGVHD).. Blood, 2009, 114, 3326-3326.	1.4	2
743	The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients. Blood, 2012, 120, 1731-1731.	1.4	2
744	Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs). Blood, 2015, 126, 4073-4073.	1.4	2
745	Transplant indications, guidelines and recommendations: Caveat Emptor. Bone Marrow Transplantation, 2022, 57, 149-151.	2.4	2
746	Surgery and Chemotherapy versus Chemotherapy Only in Older Persons with Primary Intestinal Diffuse Large B-Cell Lymphoma. Cancer Management and Research, 2021, Volume 13, 8831-8839.	1.9	2
747	Conventional interferon-Î± 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center. Haematologica, 2022, 107, 991-995.	3.5	2
748	What is the best strategy for autotransplants in cancer?. Bone Marrow Transplantation, 1992, 9, 303.	2.4	2
749	Can intensive chemotherapy cure chronic myelogenous leukemia?. Leukemia, 1992, 6, 863-5.	7.2	2
750	Chronic myelogenous leukemia: molecule to man. Henry Ford Hospital Medical Journal, 1991, 39, 108-11.	0.1	2
751	Recent radiation accidents. Chernobyl and Goiania: their impact and global implications. A presentation by Robert Peter Gale, MD, PhD. Alabama Journal of Medical Sciences, 1988, 25, 439-44.	0.1	2
752	Chronic myelogenous leukemia as a model of cancer development. Seminars in Oncology, 1995, 22, 374-9.	2.2	2
753	ASXL2 mutated myelodysplastic syndrome in a novel germline G6b variant. Leukemia Research Reports, 2022, 17, 100303.	0.4	2
754	The Russian invasion of Ukraine: Implications for haematologists. British Journal of Haematology, 2022, , .	2.5	2
755	Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplantation, 2022, 57, 1150-1163.	2.4	2
756	EVALUATION OF ANTITHYMOCYTE GLOBULIN FOR HUMAN BONE MARROW TRANSPLANTATION III. EFFECT OF ANTITHYMOCYTE GLOBULIN TREATMENT ON T CELL PRECURSORS. Transplantation, 1981, 31, 233-237.	1.0	1

#	Article	IF	Citations
757	4th International workshop on CLL. Leukemia Research, 1989, 13, 505-510.	0.8	1
758	Ph1-chromosome positive acute lymphoblastic leukemia: Is t(9;22) the initial abnormality?. American Journal of Hematology, 1993, 43, 61-62.	4.1	1
759	Blood-cell banking for workers at the Fukushima Daiichi nuclear power plant. Lancet, The, 2011, 378, 483-484.	13.7	1
760	â€˜Yet another roseâ€™. Bone Marrow Transplantation, 2013, 48, 1581-1581.	2.4	1
761	E. Donnall Thomas (1920â€“2012). Transplantation, 2013, 95, 257-258.	1.0	1
762	Professor John M. Goldman, CML Pioneer 1938â€“2013. International Journal of Hematology, 2014, 99, 103-104.	1.6	1
763	What Do Cytogenetic Abnormalities after Autotransplant Really Mean?. Biology of Blood and Marrow Transplantation, 2014, 20, 1870-1871.	2.0	1
764	Commentary. Leukemia Research, 2014, 38, 1013-1015.	0.8	1
765	Reduced-Intensity transplants, conventional transplants or chemotherapy for acute myeloid leukemia in 1st remission: who knows; ask your wife?. Leukemia, 2015, 29, 1448-1449.	7.2	1
766	Therapy of older persons with acute myeloid leukemia. Leukemia, 2015, 29, 759-759.	7.2	1
767	How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis?. Leukemia, 2016, 30, 1453-1455.	7.2	1
768	Theodor M Fliedner (1 October 1929â€“9 November 2015), transplant pioneer. Bone Marrow Transplantation, 2016, 51, 471-472.	2.4	1
769	Transplants for MDS and quality-of-life. But whose quality-of-life?. Bone Marrow Transplantation, 2016, 51, 1066-1068.	2.4	1
770	Isochromosome X in Myelodysplastic Syndrome. Acta Haematologica, 2016, 135, 37-38.	1.4	1
771	A cluster of vitreoretinal lymphoma in New York with possible link to the Chernobyl nuclear disaster. Leukemia and Lymphoma, 2018, 59, 1998-2001.	1.3	1
772	Therapy for Immunoglobulin D Plasma Cell Myeloma. Acta Haematologica, 2018, 139, 193-194.	1.4	1
773	Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplantation, 2018, 53, 932-937.	2.4	1
774	Standardizing haematopoietic cell transplants in China. Journal of Hematology and Oncology, 2018, 11, 34.	17.0	1

#	Article	IF	Citations
775	Introducing Prof. Shaun McCann, Bone Marrow Transplantationâ€™s New Sommelier. Bone Marrow Transplantation, 2018, 53, 519-520.	2.4	1
776	CBeV (cyclophosphamide, bendamustine and etoposide) pre-autotransplant conditioning in persons with lymphoma. Bone Marrow Transplantation, 2020, 55, 265-267.	2.4	1
777	Professor Shigetaka Asano: extraordinary Japanese haematologist and bon vivant February 7, 1943 to August 12, 2020. Leukemia, 2020, 34, 3107-3108.	7.2	1
778	Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre. Blood Cancer Journal, 2020, 10, 83.	6.2	1
779	Treating Plasma Cell Myeloma in Developing Countries: Does Everyone Need the Newest Drugs?. Acta Haematologica, 2020, 143, 513-515.	1.4	1
780	Liaisons Dangereuses? new drugs, physicians and the drug industry. Bone Marrow Transplantation, 2021, 56, 299-302.	2.4	1
781	Economics influences therapy decisions in chronic myeloid leukaemia: should it?. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3693-3698.	2.5	1
782	Cell therapy of chronic lymphocytic leukaemia: Transplants and chimeric antigen receptor (CAR)-T cells. Blood Reviews, 2021, 51, 100884.	5.7	1
783	The impact of cult behavior on haematopoietic cell transplant practices: believers and non-believers. Bone Marrow Transplantation, 2021, , .	2.4	1
784	Outpatient Autotransplants for Persons with Multiple Sclerosis. Blood, 2018, 132, 4618-4618.	1.4	1
785	Hematopoietic Recovery and Overall Survival after HLA-Matched Sibling Transplants for Older Patients with Severe Aplastic Anemia (SAA).. Blood, 2008, 112, 2169-2169.	1.4	1
786	Second Malignancies After Autologous Hematopoietic Cell Transplantation (AHCT) for Multiple Myeloma (MM): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. Blood, 2012, 120, 591-591.	1.4	1
787	Final Results of a Randomized Phase 2 Trial Evaluating Lower-Dose Versus Higher-Dose Pomalidomide as Therapy for Corticosteroid-Refractory Chronic Gvhd. Blood, 2016, 128, 507-507.	1.4	1
788	HGNC nomenclature for fusion genes. Leukemia, 2021, 35, 3039-3039.	7.2	1
789	Identical-Twin Transplants for B-Cell Chronic Lymphocytic Leukemia (B-CLL).. Blood, 2004, 104, 3330-3330.	1.4	1
790	ZIO-101, a Novel Organic Arsenic, Inhibits Human Myeloma Cell Growth in a SCID-hu Model.. Blood, 2006, 108, 3462-3462.	1.4	1
791	Graft-Versus-Leukemia Effect Is Equivalent in Recipients of Matched Sibling and Matched Unrelated Donor Conventional Hematopoietic Cell Transplant.. Blood, 2007, 110, 3049-3049.	1.4	1
792	Therapy-Related AML and MDS: Who Really Has It?. , 2015, 12, .		1

#	Article	IF	Citations
793	Comparison of Outcomes for Myeloablative Conditioning Regimens Combining Busulfan with Either Cyclophosphamide or Fludarabine in Children. Blood, 2016, 128, 664-664.	1.4	1
794	VEGFA rs3025020 Polymorphism Contributes to CALR-Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis. TH Open, 2021, 05, e513-e520.	1.4	1
795	Immunologic and clinical perspectives in human bone marrow transplantation. Transplantation Proceedings, 1978, 10, 265-8.	0.6	1
796	Hematopoietic growth factors in bone marrow transplantation: current and future directions. Haematologica, 1991, 76, 85-8.	3.5	1
797	BCR-ABL rearrangements in children with Philadelphia chromosome-positive chronic myelogenous leukemia. Blood, 1991, 78, 2407-10.	1.4	1
798	Hypothesis: additional cytogenetic abnormalities and progression to acute phase in chronic myelogenous leukemia. Leukemia, 1991, 5, 1012-3.	7.2	1
799	Xenophobia, T cells and a journey to a foreign land. Thymus, 1990, 16, 1-5.	0.5	1
800	Chemotherapy versus transplantation: II. Acute lymphoblastic leukemia. Haematologica, 1989, 74, 337-9.	3.5	1
801	Blood cell changes after radiation exposure. Bone Marrow Transplantation, 1988, 3, 523.	2.4	1
802	Fetal liver transplantation in hematologic disorders. Progress in Clinical and Biological Research, 1985, 193, 293-7.	0.2	1
803	Transplantation of T lymphocyte depleted bone marrow to prevent graft-versus-host disease: its implications for fetal liver transplantation. Progress in Clinical and Biological Research, 1985, 193, 315-25.	0.2	1
804	Posttransfusion hepatitis in acute myelogenous leukemia. Effect on survival. JAMA - Journal of the American Medical Association, 1980, 244, 1806-7.	7.4	1
805	Bone marrow transplantation in leukemia. Annals of Clinical Research, 1981, 13, 367-72.	0.2	1
806	Infection in Bone-Marrow Recipients. Annals of Internal Medicine, 1979, 90, 715.	3.9	0
807	Autotransplants in Advanced Non-Hodgkin Lymphoma: Are They Effective?. Cell Transplantation, 1992, 1, 343-347.	2.5	0
808	Analysing early liver dysfunction after bone marrow transplantation. Transplant Immunology, 1993, 1, 163-171.	1.2	0
809	Transplants for Acute Myelogenous Leukemia. Cancer Investigation, 1998, 16, 66-66.	1.3	0
810	Severe aplastic anaemia in a child with brachydactyly type c. British Journal of Haematology, 2003, 120, 368-369.	2.5	0

#	Article	IF	Citations
811	E. Donnall Thomas (1920â€“2012). International Journal of Hematology, 2012, 96, 679-680.	1.6	0
812	Are We Really Doing Hematopoietic Stem Cell Transplantations?. Biology of Blood and Marrow Transplantation, 2013, 19, 1656.	2.0	0
813	Nicole Muller-BÃ©rat Killmann 1932â€“2014 Leukemia pioneer. Leukemia, 2014, 28, 727-728.	7.2	0
814	John Leslie Fahey 1924â€“2014. Bone Marrow Transplantation, 2014, 49, 1453-1454.	2.4	0
815	Geoffrey Peter Herzig, MD. Leukemia, 2014, 28, 1177-1177.	7.2	0
816	Geoffrey Peter Herzig, MD (1941â€“2013): Transplant Pioneer. Bone Marrow Transplantation, 2014, 49, 597-598.	2.4	0
817	John Michael Goldman (1938-2013): Transplant Pioneer. Biology of Blood and Marrow Transplantation, 2014, 20, 435-436.	2.0	0
818	Dirk W. van Bekkum: Transplant Pioneer (1925-2015). Biology of Blood and Marrow Transplantation, 2015, 21, 1701-1702.	2.0	0
819	Dick W. van Bekkum, 1925-2015. Transplantation, 2015, 99, 2442-2443.	1.0	0
820	Ecclesiastes Strikes Again!. Biology of Blood and Marrow Transplantation, 2015, 21, 1338.	2.0	0
821	Paul Ichiro Terasaki September 10, 1929 to January 25, 2016. Transplantation, 2016, 100, 968-969.	1.0	0
822	Why do subjects on clinical trials discontinue therapy? Do we really know?. Leukemia Research, 2016, 51, 19-21.	0.8	0
823	Survival and Late Effects of Children Undergoing Myeloablative Allogeneic HCT at Less Than Three Years of Age: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2016, 22, S28-S29.	2.0	0
824	David C Seldin, MD, PhD: scientist, clinician, teacher, gentleman, 1957â€“2015. Bone Marrow Transplantation, 2016, 51, 323-323.	2.4	0
825	Paul I Terasaki (10 September, 1929â€“25 January, 2016). Bone Marrow Transplantation, 2016, 51, 621-622.	2.4	0
826	Is there consensus on consensus?. Leukemia, 2016, 30, 1229-1229.	7.2	0
827	Prof. Thomas BÃ¼chner (22 September 1934â€“5 August 2016). A career devoted to research in acute myeloid leukaemia. Leukemia Research, 2016, 49, 113-114.	0.8	0
828	Commentary: How do haematopoietic cell transplants cure leukaemia?. International Journal of Hematology, 2016, 103, 396-398.	1.6	0

#	Article	IF	Citations
829	Statistics and the Great Persky. Biology of Blood and Marrow Transplantation, 2016, 22, 589-591.	2.0	0
830	Prof. Theodor M. Fliedner (1 October 1929â€“9 November 2015): haematopoietic stem cell and radiation biology and pioneer. Leukemia, 2016, 30, 765-766.	7.2	0
831	Impact of Higher-Dose Total Body Irradiation Conditioning on Outcome of an Allogeneic Hematopoietic Cell Transplant (HCT) in the Modern Era. Biology of Blood and Marrow Transplantation, 2017, 23, S94-S95.	2.0	0
832	Johannes Joseph van Rood, Transplantation Pioneer (April 7, 1926, to July 21, 2017). Biology of Blood and Marrow Transplantation, 2017, 23, 1601.	2.0	0
833	Johannes Joseph van Rood Pioneer in immuno-genetics (7 April 1926â€“21 July 2017). Leukemia, 2017, 31, 2286-2287.	7.2	0
834	Johannes Joseph van Rood: pioneer in immuno-genetics (7 April 1926â€“21 July 2017). Bone Marrow Transplantation, 2017, 52, 1485-1486.	2.4	0
835	Improved Mortality Prognostication for Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results From a Virtual Pediatric Systems (VPS) and Center for International Blood and Marrow Transplant Research (CIBMTR) Database Merger. Biology of Blood and Marrow Transplantation, 2018, 24, S117-S119.	2.0	0
836	Prof. Franco Mandelli: Leukaemia therapy pioneer. Bone Marrow Transplantation, 2018, 53, 1375-1376.	2.4	0
837	A brief history of bone marrow transplantation. Advances in Cell and Gene Therapy, 2018, 1, e8.	0.9	0
838	High-dose chemotherapy and autotransplants for plasma cell myeloma in Jordan. Bone Marrow Transplantation, 2018, 53, 1349-1350.	2.4	0
839	Controversies and challenges in HLA-haplotype-matched transplants for leukaemia. Bone Marrow Transplantation, 2019, 54, 719-720.	2.4	0
840	Hematopoietic cell transplants in Jordan: different indications from the US and EU. Bone Marrow Transplantation, 2019, 54, 1379-1381.	2.4	0
841	Prognostic mutations in persons with isolated neutropenia myelodysplastic syndrome. Leukemia and Lymphoma, 2019, 60, 2835-2837.	1.3	0
842	Response to the Commentary on â€œIs posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myelomaâ€• Leukemia, 2019, 33, 1301-1302.	7.2	0
843	Outpatient Autotransplants for Persons with Multiple Sclerosis. Biology of Blood and Marrow Transplantation, 2019, 25, S319.	2.0	0
844	Prof. Franco Mandelli Leukaemia Visionary. May 12, 1931â€“ July 15, 2018. Leukemia, 2019, 33, 285-286.	7.2	0
845	John Hansen, MD. Bone Marrow Transplantation, 2020, 55, 836-836.	2.4	0
846	Roger Herschel Herzig: younger half of the dynamic duo which advanced leukaemia therapy and transplants: January 4, 1946 to July 18, 2020. Leukemia, 2020, 34, 2824-2825.	7.2	0

#	Article	IF	Citations
847	Academician Andrey Ivanovich Vorobiev, 1 November 1928 to 15 June 2020: founder of modern Soviet/Russian haematology. Leukemia, 2020, 34, 2539-2541.	7.2	0
848	Boris Afanasyev: The alphabet man of Russian hematopoietic cell transplantation (August 28, 1947 to) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.4	0
849	Clara Bloomfield MD: Queen of AML. Dare to cross her at your risk (May 15, 1942 to March 1, 2020). Bone Marrow Transplantation, 2020, 55, 1516-1518.	2.4	0
850	Emil J Freireich and Baruch Spinoza: birds of a feather?. Bone Marrow Transplantation, 2021, 56, 1768-1769.	2.4	0
851	Will New Drugs Replace Transplants for Chronic Lymphocytic Leukaemia?. Journal of Clinical Medicine, 2021, 10, 2516.	2.4	0
852	Professor Anton Hagenbeek 1948â€“2021: Father of MRD and lymphoma expert. Bone Marrow Transplantation, 2021, 56, 2038-2039.	2.4	0
853	Valeriy Grigorievich Savchenko: pioneering Russian hematologist: 8 January 1952â€“25 July 2021. Bone Marrow Transplantation, 2021, 56, 2613-2614.	2.4	0
854	Valeriy Grigorievich Savchenko: pioneering Russian haematologist 8 January 1952â€“25 July 2021. Leukemia, 2021, 35, 3035-3036.	7.2	0
855	Matched Related Donor Transplants for Sickle Cell Disease: Report from the Center for International Blood and Transplant Research.. Blood, 2005, 106, 2030-2030.	1.4	0
856	S-Dimethylarsinoglutathione (SGLU/ZIO101) Is a Novel Active Organic Arsenical That Displays a Unique Gene Expression Profile in Myeloma Cells.. Blood, 2006, 108, 5043-5043.	1.4	0
857	Risk Factors and Outcome after Second HLA-Matched Sibling Donor Transplantation for Graft Failure after a First HLA-Matched Sibling Transplant in Severe Aplastic Anemia.. Blood, 2007, 110, 1110-1110.	1.4	0
858	Chronic Graft-Versus-Host Disease Risk Score: A CIBMTR Analysis. Blood, 2010, 116, 898-898.	1.4	0
859	Risk-Factors for Acute Graft-Versus-Host Disease and Survival After Hematopoietic Cell Transplantation From Siblings and Unrelated Donors â€“ An Analysis of the CIBMTR. Blood, 2010, 116, 897-897.	1.4	0
860	Risk Factors for Major Transplant Related Outcomes In Pediatric Patients with Chronic Graft-Versus-Host Disease. Blood, 2010, 116, 211-211.	1.4	0
861	Results of Allogeneic Hematopoietic Cell Transplantation in Persons with Fanconi Anemia and Pretransplant Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia. Blood, 2011, 118, 838-838.	1.4	0
862	Allogeneic Hematopoietic Cell Transplantation (HCT) for Neuroblastoma (NB): The CIBMTR Experience. Blood, 2011, 118, 3074-3074.	1.4	0
863	Symptom Burden Characteristics Among Chinese Patients with Myeloproliferative Neoplasms (MPNs). Blood, 2012, 120, 1739-1739.	1.4	0
864	Lower Transplant-Related Mortality and Improved Survival for Patients with AML in First CR Receiving BuCy Compared to Cy/TBI As Myeloablative Preparation for Allogeneic Transplantation: A Report From the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood, 2012, 120, 217-217.	1.4	0

#	Article	IF	Citations
865	Comparison of the Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Across Nine Linguistic Translations Among an International Sample of 1,851 Myeloproliferative Neoplasm (MPN) Patients.. Blood, 2012, 120, 2852-2852.	1.4	0
866	John M. Goldman, DM (1938-2013). , 2014, 11, .		0
867	Present status on bone marrow transplantation in U.S.A.. Nihon Yuketsu Gakkai Zasshi = Journal of the Japan Society of Blood Transfusion / Nihon Yuketsu Gakkai, 1982, 28, 24-30.	0.1	0
868	Molecular Aberrations of Chronic Neutrophilic Leukemia: The CSF3R and SETBP1 Mutations. Blood, 2014, 124, 5578-5578.	1.4	0
869	Estimating Therapy-Related Myeloid Neoplasm Risks in the US. Blood, 2014, 124, 2617-2617.	1.4	0
870	Colony-Forming Unit Cell (CFU-C) Assays in Myelodysplastic Syndrome. Blood, 2015, 126, 2874-2874.	1.4	0
871	A Novel Erythroid Regulator MLF1IP Promotes Proliferation in Mice By Regulating Cell Cycle. Blood, 2015, 126, 2835-2835.	1.4	0
872	Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy. Blood, 2015, 126, 5175-5175.	1.4	0
873	A Rapid, Sensitive and Specific Method for Quantifying Calr Mutant Allele Burden in Persons with Myeloproliferative Neoplasms. Blood, 2015, 126, 5210-5210.	1.4	0
874	Professor Theodor Fliedner and the Atomic Hematologists. , 2016, 13, .		0
875	Patients' and Physicians' Concerns about Tyrosine Kinase-Inhibitor Therapy in Chronic Myeloid Leukemia. Blood, 2016, 128, 3092-3092.	1.4	0
876	Co-Morbidity Profile Influences Work, Daily Life and Health-Related Quality-of-Life in Persons with Chronic Myeloid Leukemia Receiving Tyrosine Kinase-Inhibitor Therapy. Blood, 2016, 128, 1927-1927.	1.4	0
877	Johannes Joseph van Rood: An Immunohematology Pioneer (1926-2017). , 2017, 14, .		0
878	Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide. Blood, 2018, 132, 3037-3037.	1.4	0
879	Osteoclast Stimulatory Transmembrane Protein (OCSTAMP) mRNA Levels and Clinical Variables in Persons with Plasma Cell Myeloma. Blood, 2018, 132, 5264-5264.	1.4	0
880	Clonal Trajectories in Persons with Acute Myeloid Leukemia and Normal Cytogenetics Relapsing after Intensive Chemotherapy and after Allotransplants. Does Pretransplant Conditioning Contribute to Mutation Topography?. Blood, 2018, 132, 2813-2813.	1.4	0
881	Genomic Landscape and Risk-Stratification for De Novo Acute Myeloid Leukemia with Normal Cytogenetics and No NPM1 or FLT3-itd Mutation. Blood, 2019, 134, 1421-1421.	1.4	0
882	Mesenchymal stromal cells and leukemia therapy in mice and man. Blood Science, 2020, 2, 106.	0.9	0

#	Article	IF	Citations
883	Short-term medical consequences of the chernobyl nuclear accident: lessons for the future. Canadian Family Physician, 1988, 34, 2565-70.	0.4	0
884	A Predictive Score for Failure-Free Survival in Persons with Chronic Myeloid Leukemia Receiving Imatinib. Blood, 2021, 138, 632-632.	1.4	0
885	Elihu H. Estey, MD: Leukaemia expert, statistician, and gentle soul (July 15, 1946â€“October 8, 2021). Bone Marrow Transplantation, 2022, 57, 140-142.	2.4	0
886	Elihu H. Estey, MD: leukemia expert, statistician, and gentle soul (July 15, 1946â€“October 8, 2021). Leukemia, 2021, 35, 3619-3621.	7.2	0
887	A Predictive Score for Outcomes of Tyrosine Kinase-Inhibitor Therapy in Persons with Chronic Myeloid Leukaemia Presenting in Accelerated Phase. Blood, 2021, 138, 636-636.	1.4	0
888	Hal E. Broxmeyer PhD: Experimental haematologist and umbilical cord blood cell transplant pioneer (27 November, 1944â€“8 December, 2021). Leukemia, 2022, , .	7.2	0
889	Progress in Transplants for Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2022, , .	7.0	0
890	Everyone is entitled to his or her own opinion but not to their own facts*. British Journal of Haematology, 2022, 196, 1290-1292.	2.5	0
891	Perspective: Chernobyl and leukemia. Leukemia, 1991, 5, 441-2.	7.2	0
892	Fetal liver cell transplantation in dogs: results with DLA-compatible and incompatible grafts. Progress in Clinical and Biological Research, 1985, 193, 195-204.	0.2	0
893	Graft-vs-leukemia following bone marrow transplantation: a model of immunotherapy in man. Progress in Clinical and Biological Research, 1987, 244, 371-90.	0.2	0
894	Clinical trials of bone marrow transplantation. Israel Journal of Medical Sciences, 1986, 22, 260-3.	0.1	0
895	Immune development in human fetal liver. Progress in Clinical and Biological Research, 1985, 193, 73-88.	0.2	0
896	Treatment of aplastic anemia. Tokai Journal of Experimental and Clinical Medicine, 1985, 10, 117-26.	0.4	0
897	Bone marrow transplantation in aplastic anemia and leukemia. Transplantation Proceedings, 1980, 12, 612-5.	0.6	0
898	Predicting results of alternative donor transplants for thalassemia using a chronic myelogenous leukemia model. Bone Marrow Transplantation, 1993, 12 Suppl 1, 82-3.	2.4	0
899	Hal E. Broxmeyer PhD: Experimental hematologist and umbilical cord blood cell transplant pioneer (27) Tj ETQq1 1 0.784314 rgBT /Ov	2.4	0
900	COVID-19 in China and the US: Differences in Hospital Admission Co-Variates and Outcomes. Vaccines, 2022, 10, 326.	4.4	0

#	Article	IF	Citations
901	Prof. Michele Baccarani. August 16, 1942 to December 20, 2021: a gifted life in haematology. Leukemia, 2022, 36, 1199-1200.	7.2	0
902	Prof. Michele Baccarani, August 16, 1942 to December 20, 2021: a gifted life in haematology. Bone Marrow Transplantation, 2022, , .	2.4	0
903	Prof. Sante Tura: Father of modern Italian haematology 20 May, 1929â€“12 October, 2021. Leukemia, 2022, 36, 1446-1447.	7.2	0
904	Prof. Sante Tura: father of modern Italian Haematology 20 May, 1929 to 12 October, 2021. Bone Marrow Transplantation, 2022, , .	2.4	0
905	Statistical challenges in haematopoietic cell transplantation. Bone Marrow Transplantation, 0, , .	2.4	0